	Pregnant women (weeks' gestation)	Postpartum women (months postpartum)

Questionnaires for the participants

Background, physical activity, diet, psychosocial wellbeing	8–9	2

Physical activity, feedback for physical activity counselling	16–18	5

Diet, feedback for dietary counselling	22–24	5

Background, physical activity, diet, psychosocial wellbeing	36–37	10

Feedback for the physical activity and dietary counselling and the study as a whole	36–37	10

Other data collection

Adverse events form	16–18, 22–24, 32–34 and 36–37	3, 5, 6 and 10

A copy of the maternity card (weight development and other data on pregnancy)	after delivery	2

Weight and waist circumference measurement form	-	2, 3, 5, 6 and 10

Blood sample	9–11 and 36–37	2–2.5 and 8

A 3-day food record prior to the blood sample	9–11 and 36–37	-

Nipple aspirate fluid (NAF) sample	-	8–12

	Pregnant women (weeks' gestation)	Postpartum women (months postpartum)

Adverse events form	16–18, 22–24, 32–34 and 36–37	3, 5, 6 and 10

A copy of the maternity card (weight development and other data on pregnancy)	after delivery	2

Weight and waist circumference measurement form	-	2, 3, 5, 6 and 10

Blood sample	9–11 and 36–37	2–2.5 and 8

A 3-day food record prior to the blood sample	9–11 and 36–37	-

Nipple aspirate fluid (NAF) sample	-	8–12


MSigDB pathway			C26 (Fold change)

1	2	3	4	5	Gene description	Gene symbol	AAV9-ev	AAV9-dnFoxO*

x	x	x	x	x	collagen, type I, alpha 2	Col1a2	−4.26	−2.31

x	x	x	x	x	collagen, type I, alpha 1	Col1a1	−5.20	−2.44

x	x	x	x	x	collagen, type VI, alpha 1	Col6a1	−2.64	−1.70

x	x	x	x	x	collagen, type VI, alpha 2	Col6a2	−2.69	−1.71

x	x	x	x	x	collagen, type VI, alpha 3	Col6a3	−3.55	−1.75

x	x	x			thrombospondin 2	Thbs2	−1.62	−1.07

x	x	x			tenascin C (hexabrachion)	Tnc	−2.43	−1.45

x		x			integrin, beta 6	Itgb6	−10.24	−2.20

x		x			cartilage oligomeric matrix protein	Comp	−2.48	−1.05

x		x			chondroadherin	Chad	−16.34	−2.40

	x				fibrillin 1	Fbn1	−2.86	−1.71

		x			Rho-associated, coiled-coil protein kinase2	Rock2	−1.98	−1.16

			x	x	collagen, type XIV, alpha 1 (undulin)	Col14a1	−2.08	−1.26

			x	x	procollagen C-endopeptidase enhancer	Pcolce	−1.81	−1.10

			x		matrix metallopeptidase 15	Mmp15	−3.12	−2.06

DAVID annotation

1	2	3	4	5

x	x	x			myozenin 3	Myoz3	−5.53	−1.99

x	x	x			integrin beta 1 binding protein 2 (melusin)	Itgb1bp2	−4.25	−2.07

x	x	x			junctophilin 2	Jph2	−3.95	−2.10

x	x	x			synemin, intermediate filament protein	Synm	−2.61	−1.47

x	x	x			homer homologue 1	Homer1	−2.26	−1.45

x	x	x			LIM domain binding 3/Zasp/Cypher	Ldb3	−1.84	−1.14

			x	x	fibromodulin	Fmod	−3.29	−1.29

			x	x	keratocan	Kera	−14.38	−3.30

			x	x	lumican	Lum	−2.47	−1.43

MSigDB pathway			C26 (Fold change)

1	2	3	4	5	Gene description	Gene symbol	AAV9-ev	AAV9-dnFoxO*

x	x	x	x	x	collagen, type VI, alpha 3	Col6a3	−3.55	−1.75

x	x	x			thrombospondin 2	Thbs2	−1.62	−1.07

x	x	x			tenascin C (hexabrachion)	Tnc	−2.43	−1.45

x		x			integrin, beta 6	Itgb6	−10.24	−2.20

x		x			cartilage oligomeric matrix protein	Comp	−2.48	−1.05

x		x			chondroadherin	Chad	−16.34	−2.40

	x				fibrillin 1	Fbn1	−2.86	−1.71

		x			Rho-associated, coiled-coil protein kinase2	Rock2	−1.98	−1.16

			x	x	collagen, type XIV, alpha 1 (undulin)	Col14a1	−2.08	−1.26

			x	x	procollagen C-endopeptidase enhancer	Pcolce	−1.81	−1.10

			x		matrix metallopeptidase 15	Mmp15	−3.12	−2.06

DAVID annotation

1	2	3	4	5

x	x	x			myozenin 3	Myoz3	−5.53	−1.99

x	x	x			integrin beta 1 binding protein 2 (melusin)	Itgb1bp2	−4.25	−2.07

x	x	x			junctophilin 2	Jph2	−3.95	−2.10

x	x	x			synemin, intermediate filament protein	Synm	−2.61	−1.47

x	x	x			homer homologue 1	Homer1	−2.26	−1.45

x	x	x			LIM domain binding 3/Zasp/Cypher	Ldb3	−1.84	−1.14

			x	x	fibromodulin	Fmod	−3.29	−1.29

			x	x	keratocan	Kera	−14.38	−3.30

			x	x	lumican	Lum	−2.47	−1.43


Project	Number of participants interviewed

Total non-Indigenous participants	28 (19 F, 9 M)

Total Indigenous research participants	8 (6 F, 2 M)

TOTAL research participants	36 (24 F, 11 M)


Peak number	Mass	Composition of ion

1	357.13	B ion: CHR

2	458.24	B ion: CHR_K

3	616.28	B ion: CHR_K_OH-D

4	718.32	B ion: CHR_K_OH-D_T

5	818.39	B ion: CHR_K_OH-D_T_T

6	905.42	B ion: CHR_K_OH-D_T_T_S

7	1036.41	B ion: CHR_K_OH-D_T_T_S_OH-D

Y1	1067.48	Y ion resulting from loss of chromophore acyl group


Groups	Dose (mg/kg)	Water (ml)	Food (g)	Weight gain (day 7)	Weight gain (day 14)

Contro		6.190 ± 0.31	4.697 ± 0.14	1	1.


	ABSOLUTE LATENCIES

GA/P	I	III	V

Mean	SD	Mean	SD	Mean	SD

Full term/P2	1.71	0.30	4.32	0.33	6.50	0.33

Full term/P3	1.71	0.20	3.97	0.28	6.23	0.30


Variable	Odds ratio	95% CI

Joint family	4.03	2.41-6.18

> 2 birth order	3.09	2.16-4.19

Mother's education ≤ 6th standard	3.81	2.37-5.96

Mother working	4.47	3.04-6.98

Variable	Odds ratio	95% CI

Joint family	4.03	2.41-6.18

> 2 birth order	3.09	2.16-4.19

Mother's e	3.81	2.37-5.96

ducation ≤ 6th standard

Mother working	4.47	3.04-6.98


AA + White

AA

White

AA-Whitedifference


Final identification (no of isolates)	Number of isolates

Conventional identification method (Vitek 2)	VITEK MS identification	Bruker MS identification	16S rRNA sequence results (number of discrepant organisms sequenced)

No ID	Mis - ID	No ID	Mis - ID	No ID	Mis - ID

Haemophilus influenzae (8)	0	0	0	0	0	2 (score <1.7)	H. influenzae (2)

Neisseria cinerea (1)	0	0	0	1 (Neisseria subflava)	0	1 (Neisseria sicca)	N. cinerea (1)

Neisseria subflava (5)	NA	NA	0	0	0	Neisseria flava (5)	N. subflava (5)

Neisseria meningitidis (1)	0	0	0	0	0	0

Moraxella catarrhalis (1)	0	0	0	0	0	0


Total expressed features	Overlapping features	EM	PL	ES	TS

13,718	EM		9,840	9,212	9,314

10,559	PL			8,508	8,881

9,667	ES				8,816

9,840	TS

Total expressed U-clusters	Overlapping U-clusters	EM	PL	ES	TS

11,360	EM		8,271	7,749	7,853

8,828	PL			7,181	7,492

8,101	ES				7,435

8,271	TS

Total expressed transcripts	Overlapping transcripts	EM	PL	ES	TS

11,762	EM		8,516	7,980	8,090

9,108	PL			7,386	7,718

8,357	ES				7,657

8,534	TS

Total expressed features	Overlapping features	EM

13,718	EM

10,559	PL

9,667	ES

9,840	TS

Total expressed U-clusters	Overlapping U-clusters	EM

11,360	EM

8,828	PL

8,101	ES

8,271	TS

Total expressed transcripts	Overlapping transcripts	EM

11,762	EM

9,108	PL

8,357	ES

8,534	TS


Primers and probes	Nucleic acid sequences of primers and probes

qPCR Zika virus (ZIKV)

 ZIKV forward	5-nt9271AARTACACATACCARAACAAAgTggT9297–3’

 ZIKV reverse	5′ nt9352-TCCRCTCCCYCTYTggTCTTg-9373 -3’

 ZIKV probe	nt 9304-FAM-CTYAgACCAgCTgAAR-BBQ-9320

qPCR Dengue total (DENV 1–4 system)

 DENT forward	5′- AGGACYAGAGGTTAGAGGAGA - 3’

 DENT reverse	5′- CGYTCTGTGCCTGGAWTGAT −3’

 DENT probe	FAM-ACAGCATATTGACGCTGGGARAGACC-TAMRA

qPCR Dengue subtypes (DENV1, DENV2, DENV3)

 DEN1 forward	5′ ATACCYCCAACAGCAGGAATT - 3’

 DEN1 reverse	5′ AGCATRAGGAGCATGGTCAC −3’

 DEN1 probe	FAM-TTGGCTAGATGGRGCTCATTCAAGAAGAAT-TAMRA

 DEN2 forward	5′ TGGACCGACAAAGACAGATTCTT 3’

 DEN2 reverse	5′ CGYCCYTGCAGCATTCCAA 3’

 DEN2 probe	FAM-CGCGAGAGAAACCGCGTGTCRACTGT-TAMRA

 DEN3 forward	5′ AAGACGGGAAAACCGTCTATCAA 3’

 DEN3 reverse	5′ TTGAGAATCTCTTCGCCAACTG 3’

 DEN3 probe	FAM-ATGCTGAAACGCGTGAGAAACCGTGT-TAMRA

qPCR Chikungunya (CHIK)

 CHIK forward	5′- AAGCTYCGCGTCCTTTACCAAG - 3’

 CHIK reverse	5′- CCAAATTGTCCYGGTCTTCCT −3’

 CHIK probe	FAM-CCAATGTCYTCMGCCTGGACACCTTT-TAMRA

qPCR Rift Valley fever virus (RVFV)

 RVFV forward	5′- AAA ggA ACA ATg gAC TCT ggT CA - 3’

 RVFV reverse	5′- CAC TTC TTA CTA CCA TTC CTC CAA T − 3’

 RVFV probe	FAM-AAA gCT TTg ATA TCT CTC AgT gCC CCA A -TAMRA

qPCR West Nile virus (WNV)

 WNV3p forward	5′ Agg TTA gWg gAg ACC CCg T - 3’

 WNV3p reverse	5′ ggT TgT gCA gAg CAg AAg ATC −3’

 WNV3p probe	FAM-CGGTTCCGGCGGTGGTTTCT-TAMRA

Conventional PCR Crimean-Congo haemorrhagic fever virus (CCHFV)

 CCHFV forward	5′ – TGGACACCTTCACAAACTC - 3’

 CCHFV reverse	5′ – GACAAATTCCCTGCACCA - 3’

qPCR Hepatitis E virus (HEV)

 HEV forward	5′ GCCCGGTCAGCCGTCTGG −3’

 HEV reverse	5′-CTGAGAATCAACCCGGTCAC −3’

 HEV probe	FAM-CGGTTCCGGCGGTGGTTTCT-TAMRA

Primers and probes	Nucleic acid sequences of primers and probes

CCHFV forward	5′ – TGGACACCTTCACAAACTC - 3’

CCHFV reverse	5′ – GACAAATTCCCTGCACCA - 3’

qPCR Hepatitis E virus (HEV)

HEV forward	5′ GCCCGGTCAGCCGTCTGG −3’

HEV reverse	5′-CTGAGAATCAACCCGGTCAC −3’

HEV probe	FAM-CGGTTCCGGCGGTGGTTTCT-TAMRA


Item number	Question description	Expert raters	I-CVIa

		1	2	3	4

Q1	Lifetime prevalence	4	4	4	4	1.00

Q2	Age of onset	4	4	4	4	1.00

Q3	Recurrent NSLBPc	4	4	4	2	0.75

Q4	Frequency of recurrent NSLBP	4	4	4	3	1.00

Q5	Duration of recurrent NSLBP	2	4	4	4	0.75

Q6	Intensity of recurrent NSLBP	4	4	4	4	1.00

Q7	Sciatica	4	4	4	4	1.00

Q8	Point prevalence	4	4	4	4	1.00

Q9	Point pain intensity	4	4	4	4	1.00

Q10	Medical treatment	4	4	4	4	1.00

Q11a	Sitting on a chair	4	4	4	4	1.00

b)	Reaching up	4	4	4	4	1.00

c)	Standing	4	4	4	4	1.00

d)	Walking	4	4	4	4	1.00

e)	Sporting activity	4	4	4	4	1.00

f)	Bending	4	4	4	4	1.00

g)	School-bag carrying	4	4	4	4	1.00

h)	Sitting up in bed	4	4	4	4	1.00

i)	Running	4	4	4	4	1.00

Q12	Absenteeism	3	4	4	4	1.00

Q13	Bag carriage	4	4	4	4	1.00

Q14	Perception school-bag weight	4	4	4	3	1.00

Q15	Duration of carrying school-bag	3	4	4	4	1.00

Q16	Method of carrying school-bag	4	4	4	4	1.00

Q17	Sports participation	4	4	4	4	1.00

Q18	Type of sport	4	4	4	4	1.00

Q19	Sports duration	4	4	4	4	1.00

Q20	Sedentary time	3	4	4	4	1.00

Q21	Smoking	4	4	4	1	0.75

Q22	Past week smoking	4	4	4	1	0.75

	dTotal agreement=0.86 bS-CVI/Ave = 0.97

Question description	Expert raters	I-CVIa

	1	2	3	4

Lifetime prevalence	4	4	4	4	1.00

Age of onset	4	4	4	4	1.00

Recurrent NSLBPc	4	4	4	2	0.75

Frequency of recurrent NSLBP	4	4	4	3	1.00

Duration of recurrent NSLBP	2	4	4	4	0.75

Intensity of recurrent NSLBP	4	4	4	4	1.00

Sciatica	4	4	4	4	1.00

Point prevalence	4	4	4	4	1.00

Point pain intensity	4	4	4	4	1.00

Medical treatment	4	4	4	4	1.00

Sitting on a chair	4	4	4	4	1.00

Reaching up	4	4	4	4	1.00

Standing	4	4	4	4	1.00

Walking	4	4	4	4	1.00

Sporting activity	4	4	4	4	1.00

Bending	4	4	4	4	1.00

School-bag carrying	4	4	4	4	1.00

Sitting up in bed	4	4	4	4	1.00

Running	4	4	4	4	1.00

Absenteeism	3	4	4	4	1.00

Bag carriage	4	4	4	4	1.00

Perception school-bag weight	4	4	4	3	1.00

Duration of carrying school-bag	3	4	4	4	1.00

Method of carrying school-bag	4	4	4	4	1.00

Sports participation	4	4	4	4	1.00

Type of sport	4	4	4	4	1.00

Sports duration	4	4	4	4	1.00

Sedentary time	3	4	4	4	1.00

Smoking	4	4	4	1	0.75

Past week smoking	4	4	4	1	0.75

dTotal agreement=0.86 bS-CVI/Ave = 0.97


	Symptomatic Group (n = 30)	Asymptomatic Group (n = 30)	Overall (n = 60)

GSRS-IBS Subdomains	Score ≥ 2 (Any Discomfort), n	Score ≥ 4 (Moderate to Severe Discomfort), n	Score ≥ 2 (Any Discomfort), n	Score ≥ 4 (Moderate to Severe Discomfort), n	Score ≥ 2 (Any Discomfort), n

Pain (Q1 or 2)	15 (50%)	11 (37%)	1 (3%)	0	16 (27%)

Bloating (Q3, 4 or 13)	24 (80%)	3 (10%)	7 (23%)	1 (3%)	31 (52%)

Constipation (Q5 or 8)	17 (57%)	8 (27%)	8 (27%)	3 (10%)	25 (42%)

Diarrhoea (Q6, 7, 9 or 10)	24 (80%)	10 (33%)	6 (20%)	0	30 (50%)

Satiety (Q11 or 12)	15 (50%)	3 (10%)	5 (17%)	2 (7%)	20 (33%)

GSRS-IBS Subdomains

Pain (Q1 or 2)

Bloating (Q3, 4 or 13)

Constipation (Q5 or 8)

Diarrhoea (Q6, 7, 9 or 10)

Satiety (Q11 or 12)


Time	Monday	Tuesday	Wednesday	Thursday	Friday

8 am – 10 am	Lecture (C1) / Morning session (C2)	Lecture (C1) / Morning session (C2)	Social and Population Health	Lecture (C1)/ Morning session (C2)	Primary Health / Community attachment

10 am-12:30 pm	Bedside teaching	Inpatient/ outpatient care	Inpatient/ outpatient care	Bedside teaching

12:30 pm- 2 pm	Lunch	Lunch	Lunch	Lunch	Lunch

2 pm–4 pm	Inpatient/ outpatient care	PCD	Inpatient/ outpatient care	Inpatient/ outpatient care	Whole group session seminar/journal club/grand round

4 pm-5:30 pm	Inpatient/ outpatient care

10 am-12:30 pm	Bedside teaching	Inpatient/ outpatient care	Inpatient/ outpatient care	Bedside teaching	Primary Health / Community attachment

12:30 pm- 2 pm	Lunch	Lunch	Lunch	Lunch	Lunch

2 pm–4 pm	Inpatient/ outpatient care	PCD	Inpatient/ outpatient care	Inpatient/ outpatient care	Whole group session seminar/journal club/grand round

4 pm-5:30 pm	Inpatient/ outpatient care


Adverse events	Placebo (n = 23)	100 mg/day 5-Loxin® (n = 24)	250 mg/day 5-Loxin® (n = 23)

Diarrhoea	3	2	2

Nausea	1	3	2

Vomiting	1	1	1

Abdominal pain	4	2	2

Pedal edema	0	1	0

Itching	2	1	4

General weakness	2	4	2

Constipation	0	0	1

Mild fever (up to 37.5°C)	1	2	2

Stomach burn	4	0	3

Allergya	3	0	1

Headache	0	0	1

Miscellaneousb	9	2	6

Sum of events	30	18	27

Adverse events	Placebo (n = 23)

Diarrhoea	3

Nausea	1

Vomiting	1

Abdominal pain	4

Pedal edema	0

Itching	2

General weakness	2

Constipation	0

Mild fever (up to 37.5°C)	1

Stomach burn	4

Allergya	3

Headache	0

Miscellaneousb	9

Sum of events	30


	Femoral offset (mm)

	Operated	Contralateral	Average diff	< 4.62 mm diff	P value

Hip Resurfacing	50.71	50.63	-0.08	50%	0.9

Large-head metal on metal	51	56.56	+5.56	35%	0.0002

Total hip replacement	47.61	56.23	+8.62	30%	0.0003

	Femoral offset (mm)

	Operated	Contralateral	Average diff	< 4.62 mm diff	P value

Hip Resurfacing	50.71	50.63	-0.08	50%	0.9

Large	51			3

	Femoral offset (mm)

	Operated	Contralateral	Average diff	< 4.62 mm diff	P value

-head metal on metal		56.56	+5.56	5%	0.0002

Total hip replacement	47.61	56.23	+8.62	30%	0.0003


Author	Country	Patients for score derivation (n)	Outcome	Patients with outcome n (%)	Maximum time between assessment and outcome measure	Variables	Performance

Soxa 1990 [35]	USA	1074	MIAnginaCoronary insufficiency	424 (39.5)	1 year	AgeGenderExertional painPatient stops activities when pain occursPMH of MISmokingPain relived by NTG	For score > 4S:0.99Sp:0.18PPV:0.45NPV:0.98

Gencer 2010 [36]	Switzerland Germany	661	CAD	85 (12.9)	1 year	AgeGenderCV Risk KnownPain locationPain duration Exertional painPain on palpationPMH of CVD	AUC: 0.95 (0.92-0.97)

For scores < 5(Lowest 5 % for patients with CAD):S:0.98Sp:0.71NPV:0.99

Bösner 2010 [30]	Germany Switzerland	1199	CAD	180 (15.0)	6 months	AgeGenderExertional painPMH of CVDPatient assumes pain of cardiac originPain on palpation	AUC: 0.90 (0.87-0.93)

For a cut-off value of 3 (risk of CAD > 35 %): S:0.86(0.79-0.92)Sp:0.75(0.72-0.78)PPV:0.35(0.29-0.41)NPV:0.97(0.96-0.98)

Author	Country	Patients for score derivation (n)	Outcome	Patients with outcome n (%)	Maximum time between assessment and outcome measure	Variables	Performance

Bösner 2010 [30]	Germany Switzerland	1199	CAD	180 (15.0)	6 months	AgeGenderExertional painPMH of CVDPatient assumes pain of cardiac originPain on palpation	AUC: 0.90 (0.87-0.93)

For a cut-off value of 3 (risk of CAD > 35 %): S:0.86(0.79-0.92)Sp:0.75(0.72-0.78)PPV:0.35(0.29-0.41)NPV:0.97(0.96-0.98)


SCOP superfamily	PFAM name	Accession number

Ig	V-set	PF07686

	I-set	PF07679

	C2-set	PF05790

	C1-set	PF07654

	Ig	PF00047

	Ig_2	PF13895

	ICAM_N	PF03921

E-SET	Alpha_amylase_N	PF02903

	arrestin_N	PF00339

	arrestin_C	PF02752

	CelD_N	PF02927

	peptidaseC25	PF03785

	TIG	PF01833

	RHD	PF00554

	DUF291	PF03442

	Filamin	PF00630

	He_Pig	PF05345

Fibronectin type 3	FN3	PF00041

	tissue_fac	PF01108

	lep_receptor_Ig	PF06328

PKD	PKD	PF00801

	PPC	PF04151

	HYR	PF02494

β-Galactosidase/β-Glucuronidase	Glycol_hydro_2	PF00703

Cu, Zn Superoxide dismutase-like	Sod_Cu	PF00080

PapD-like	Pili_assembly_C	PF02753

	pili_assembly_N	PF00345

Invasin/intimin cell-adhesion fragments	Big_1	PF02369

	Big_2	PF02368

	Big_3	PF07523

	Big_4	PF07532

Clathirin adaptor appendage domain	Alpha_adaptin_C2	PF02883

Transglutaminase N-terminal domain	Transglut_N	PF00868

Cadherin-Like	Cadherin domain	PF00028

Actinoxanthin-like	Neocarzinostatin family	PF00960

CBD9-like	Domain of unknown function	PF06452

laminA/C globular tail domain	Intermediate filament tail domain	PF00932

Other Ig-like	C type Lectin	PF00059

	BACON	PF13004

	MucBP	PF06458

SCOP superfamily	PFAM name	Accession number

	C1-set	PF07654

	Ig	PF00047

	Ig_2	PF13895

	ICAM_N	PF03921

E-SET	Alpha_amylase_N	PF02903

	arrestin_N	PF00339

	arrestin_C	PF02752

	CelD_N	PF02927

	peptidaseC25	PF03785

	TIG	PF01833

	RHD	PF00554

	DUF291	PF03442

	Filamin	PF00630

	He_Pig	PF05345

Fibronectin type 3	FN3	PF00041

	tissue_fac	PF01108

	lep_receptor_Ig	PF06328

PKD	PKD	PF00801

	PPC	PF04151

	HYR	PF02494

β-Galactosidase/β-Glucuronidase	Glycol_hydro_2	PF00703

Cu, Zn Superoxide dismutase-like	Sod_Cu	PF00080

PapD-like	Pili_assembly_C	PF02753

	pili_assembly_N	PF00345

Invasin/intimin cell-adhesion fragments	Big_1	PF02369

	Big_2	PF02368

	Big_3	PF07523

	Big_4	PF07532

Clathirin adaptor appendage domain	Alpha_adaptin_C2	PF02883

Transglutaminase N-terminal domain	Transglut_N	PF00868

Cadherin-Like	Cadherin domain	PF00028

Actinoxanthin-like	Neocarzinostatin family	PF00960

CBD9-like	Domain of unknown function	PF06452

laminA/C globular tail domain	Intermediate filament tail domain	PF00932

Other Ig-like	C type Lectin	PF00059

	BACON	PF13004

	MucBP	PF06458


	Total weight change over 17 days compared to control/% change	Daily weight change (per day over 17 days) compared to control (kg)

Treatment 1 - Control

Treatment 2–0.5×	0.633 kg/11.1%	0.037 kg

Treatment 3 - lx	−0.325 kg/−5.7%	−0.019 kg

Treatment 4 - 2×	0.807 kg/14.1%	0.047 kg

	Total weight change over 17 days compared to control/% change

Treatment 1 - Control

Treatment 2–0.5×	0.633 kg/11.1%

Treatment 3 - lx	−0.325 kg/−5.7%

Treatment 4 - 2×	0.807 kg/14.1%

Daily weight change (per day over 17 days) compared to control (kg)

Treatment 1 - Control

0.037 kg

−0.019 kg

0.047 kg


Key obstetric danger signs	Place of delivery	P-values*

Cases (n = 118)	Controls (n = 238)

Frequency (%)	Frequency (%)

Key danger sign during pregnancy

Vaginal bleeding	86(72.9)	117(49.2)	<0.001

Swelling of the face and hands	56(47.5)	35(14.7)	<0.001

Blurring (difficult) vision	26(22.0)	26(10.9)	0.005

Key danger sign during Labour and delivery

Excess vaginal bleeding	93(78.8)	89(37.4)	<0.001

Prolonged labour (>12 hours)	76(64.4)	113(47.5)	0.003

Retained placenta(>30minuts)	54(45.8)	74(31.1)	0.007

Convulsions	13(11.0)	2(0.8)	<0.001

Key danger sign during postpartum period

Vaginal bleeding	71(60.2)	76(31.9)	<0.001

Increased body temp (fever)	8(6.8)	11(4.6)	0.454

Offensive vaginal bleeding	21(17.8)	13(5.5)	<0.001


	Bipolar disorder	0.1382	0.0605	0.0223

	Childhood cognitive ability	−0.1528	0.0891	0.0864

	Major depressive disorder	0.5902	0.1015	6.03 × 10−9

	Neuroticism	0.6150	0.038	7.34 × 10−59

	Schizophrenia	0.2490	0.0386	1.14 × 10−10

	Verbal-numerical reasoninga	−0.1379	0.0596	0.0206


Average number of antenatal visits	Average number in intervention arm	Difference	Power	Sample sizeper arm

8.9	10.9	2	90%	190

9.4	10.9	1.5	90%	337


2001 NCEP ATP III definition	AHA/NHLBI definition	IDF definition

(any three of five)	(any three of five)	(requiredaand any two of four criteria left)

BMI ≥30 kg/m2	BMI ≥ 30 kg/m2	BMI ≥30 kg/m2 a

TG ≥150 mg/dl	TG ≥150 mg/dl or treatment for elevated TG	TG ≥150 mg/dl or treatment for elevated TG

C-HDL <40 mg/dl in men	C-HDL <40 mg/dl in men	C-HDL <40 mg/dl in men

C-HDL <50 mg/dl in women	C-HDL <50 mg/dl in women	C-HDL <50 mg/dl in women

Blood pressure ≥130/85 mmHg or previous hypertension diagnosis	Blood pressure ≥130/85 mmHg or previous hypertension diagnosis	Blood pressure ≥130/85 mmHg or previous hypertension diagnosis

Fasting glucose ≥110 mg/dl or previous type 2 DM	Fasting glucose ≥100 mg/dl or previous type 2 DM	Fasting glucose ≥100 mg/dl or previous type 2 DM

2001 NCEP ATP III definition	AHA/NHLBI definition

(any three of five)	(any three of five)

BMI ≥30 kg/m2	BMI ≥ 30 kg/m2

TG ≥150 mg/dl	TG ≥150 mg/dl or treatment for elevated TG

C-HDL <40 mg/dl in men	C-HDL <40 mg/dl in men

C-HDL <50 mg/dl in women	C-HDL <50 mg/dl in women

Blood pressure ≥130/85 mmHg or previous hypertension diagnosis	Blood pressure ≥130/85 mmHg or previous hypertension diagnosis

Fasting glucose ≥110 mg/dl or previous type 2 DM	Fasting glucose ≥100 mg/dl or previous type 2 DM

IDF definition

(requiredaand any two of four criteria left)

BMI ≥30 kg/m2 a

TG ≥150 mg/dl or treatment for elevated TG

C-HDL <40 mg/dl in men

C-HDL <50 mg/dl in women

Blood pressure ≥130/85 mmHg or previous hypertension diagnosis

Fasting glucose ≥100 mg/dl or previous type 2 DM


Metastasis location	Upper thoracic section (174)	Middle thoracic section (132)	Lower thoracic section (80)	Total	P


	No toxicity	Grade 1	Grade 2	Grade 3	Grade 4

Dyesthesia	12.8%	70.9%	11.6%	4.7%	0%

Paresthesia	5.7%	66.3%	19.8%	7%	1.2%

	No toxicity

Dyesthesia	12.8%

Paresthesia	5.7%


	Categories	Number (%)

Age range (years)	2–4	2 (3%)

4–12	19 (28%)

12–19	22 (33%)

19–40	18 (27%)

40–50	3 (4.5%)

>50	3 (4.5%)

Type of abnormal foot position	Equinus	18 (27%)

Flatfoot (flexible)	15 (22%)

Flatfoot (rigid)	12 (18%)

Other	7 (10.5%)

No problems	10 (15%)

Nil response	5 (7.5%)

Type of foot support	Semi-orthopedic footwear	14 (21%)

Orthopedic footwear	17 (25.5%)

Ankle-foot orthosis (AFO)	15 (22%)

Other	4 (6%)

Not required	10 (15%)

Nil response	7 (10.5%)

Full foot on the floor (when standing with bare feet)	Yes	24 (36%)

Partial	4 (6%)

No	30 (45%)

Nil response	9 (13%)

Symmetrical weight bearing through both legs (when standing)	Yes	12 (18%)

No	46 (69%)

Nil response	9 (13%)

	Categories	Number (%)

Age range (years)	2–4	2 (3%)

4–12	19 (28%)

12–19	22 (33%)

19–40	18 (27%)

40–50	3 (4.5%)

>50	3 (4.5%)

Type of abnormal foot position	Equinus	18 (27%)

Flatfoot (flexible)	15 (22%)

Flatfoot (rigid)	12 (18%)

Other	7 (10.5%)

No problems	10 (15%)

Nil response	5 (7.5%)

Type of foo	Semi-orthopedic footwear	14 (21%)

Orthopedic footwear	17 (25.5%)

Ankle-foot orthosis (AFO)	15 (22%)

Oth	4 (6

	Categories	Number (%)

t support	er	%)

Not required	10 (15%)

Nil response	7 (10.5%)

Full foot on the floor (when standing with bare feet)	Yes	24 (36%)

Partial	4 (6%)

No	30 (45%)

Nil response	9 (13%)

Symmetrical weight bearing through both legs (when standing)	Yes	12 (18%)

No	46 (69%)

Nil response	9 (13%)


	Subj.	Resp.	Resp. Ad.	Heart	Heart Ad.

		[min−1]	[min−1]	[bpm]	[bpm]

	1	0.0 (0	0.0 (0.3)	-0.3


Cell line	HPV DNA	Cisplatin IC50 (μmol/L)

UPCI-SCC-003	(−)	1.7

UPCI-SCC-036	(−)	3.0

UPCI-SCC-089	(−)	1.2

UPCI-SCC-090	(+)	5.7

UPCI-SCC-152	(+)	4.6

UPCI-SCC-154	(+)	2.0

Cell line	HPV DNA	Cisplatin IC50 (μmol/L)

UPCI-SCC-003	(−)	1.7

UPCI-SCC-036	(−)	3.0

UPCI-SC	(−)	1

Cell line	HPV DNA	Cisplatin IC50 (μmol/L)

C-089		.2

UPCI-SCC-090	(+)	5.7

UPCI-SCC-152	(+)	4.6

UPCI-SCC-154	(+)	2.0


Patient	Pre-operative cretinine	Post-operative creatinine	Voiding	Incontience	Dialysis

1	Normal	Normal	Spontaneous	−	−

2	Elevated	Normal	Spontaneous	−	−

3	Elevated	Elevated	Vesicostomy	−	+

4	Normal	Normal	Spontaneous	−	−

5	Normal	Normal	Spontaneous	−	−

6	Elevated	Elevated	CIC	−	+

7	Normal	Normal	Spontaneous	−	−

8	Normal	Normal	Spontaneous	−	−

9	Normal	Normal	Spontaneous	Frequency/urgency	−

10	Normal	Normal	Spontaneous	−	−

11	Normal	Normal	Spontaneous	−	−

Patient	Pre-operative cretinine	Post-operative creatinine	Voiding

1	Normal	Normal	Spontaneous

2	Elevated	Normal	Spontaneous

3	Elevated	Elevated	Vesicostomy

4	Normal	Normal	Spontaneous

5	Normal	Normal	Spontaneous

6	Elevated	Elevated	CIC

7	Normal	Normal	Spontaneous

8	Normal	Normal	Spontaneous

9	Normal	Normal	Spontaneous

10	Normal	Normal	Spontaneous

11	Normal	Normal	Spontaneous

Incontience	Dialysis

−	−

−	−

−	+

−	−

−	−

−	+

−	−

−	−

Frequency/urgency	−

−	−

−	−


Cell line	HEK 293T	HeLa

Replicate number	1	2	3	1	2	3

Telomerase activity ratio (flow through/input)	0.65	0.48	0.44	0.56	0.37	0.33

hTR ratio (flow through/input)	0.94	0.84	0.77	0.91	0.88	0.88

Estimated number of assembled telomerase monomer per cella	146	245	332	255	255	222

Million hTR per μl elutionb	9.2	8.2		1.2	1.3	1.4

Million hTERT per μl elution	15	11		1.7	3.1	3.3

Estimated number of hTERT protein per cellc	237	322		382	608	534


Authors	Number of patients/centres included	Epoetin isoform	Variables explored (inputs)	Predictions (outputs)

Gabutti et al (present study)	432/29	Beta	Sex; age; weight, presence or absence of a diabetes mellitus and/or a cardiomyopathy with EF<50%; haemoglobin; creatinine; BUN; pH; ionized calcium; albumin; CRP; ferritin; PTH; epoetin and iron dose; epoetin administration route sc vs. iv; Kt/V	Epoetin dose and follow-up haemoglobin

Bellazzi [24]	10/1	n.s.	Sex; age; haemoglobin; calcium; PTH; epoetin dose and others non specified	Follow-up haemoglobin

Martin Guerriero et al [20]	110/1	Alpha and beta	Age; weight; haemoglobin; ferritin; epoetin dose; isoform and number of administrations weekly; iron dose	Epoetin dose

Gaweda et al [25]	209/1	n.s.	Haematocrit; albumin; ferritin; iron saturation; PTH; epoetin and iron dose; Kt/V	Follow-up haematocrit

Jacobs et al [26]	166/n.s.	n.s.	Haematocrit; albumin; ferritin; iron saturation; PTH; epoetin and iron dose; Kt/V	Follow-up haematocrit

Authors	Number of patients/centres included	Epoetin isoform	Variables explored (inputs)	Predictions (outputs)

Martin Guerriero et al [20]	110/1	Alpha and beta	Age; weight; haemoglobin; ferritin; epoetin dose; isoform and number of administrations weekly; iron dose	Epoetin dose

Gaweda et al [25]	209/1	n.s.	Haematocrit; albumin; ferritin; iron saturation; PTH; epoetin and iron dose; Kt/V	Follow-up haematocrit

Jacobs et al [26]	166/n.s.	n.s.	Haematocrit; albumin; ferritin; iron saturation; PTH; epoetin and iron dose; Kt/V	Follow-up haematocrit


	IORNS SRI r	IORNS DRI r	IORNS PSI r	IORNS TOT r

LASC severity	.22	.40**	−.16	.33

LASC global	.25	.56**	−.34*	.52**

LASC B “re-experiencing”	.09	.29	−.18	.21

LASC C “avoidance”	.25	.46**	−.11	.43**

LASC D “hyperarousal”	.15	.28	−.11	.23


Urban Area	Type of Mobile Source Pollution	EC	NOx	CO

Atlanta, GA	Diesel	0.64	0.36	*

Gasoline	*	0.38	0.62

Combined	0.32	0.36	0.32

Denver, CO	Diesel	0.70	0.30	*

Gasoline	*	0.32	0.68

Combined	0.33	0.29	0.37

Houston, TX	Diesel	0.55	0.44	*

Gasoline	*	0.35	0.65

Combined	0.22	0.38	0.40

Urban Area	Type of Mobile Source Pollution	EC	NOx	CO

Atlanta, GA	Diesel	0.64	0.36	*

Gasoline	*	0.38	0.62

Combined	0.32	0.36	0.32

Den	Die		0.3


Parameter	Ethnic group	Rest of the sample	P value

Age (years± standard deviation)	39.5±14	39.1±13	NS

Gender

% Female	51.5	58	NS

% Male	48.5	42	NS

Education level

% Without studies or elementary school	48.9	44.8	<0.05

% High-school	43.4	46.7	<0.05

% College	7.7	8.5	NS

% Self-reported gingival bleeding	5.1	3.4	<0.05

GDP	0.63	0.70	<0.05

HDI	0.75	0.78	<0.05

UBNI	32	20.7	<0.05

Parameter	Ethnic group	Rest of the sample	P value

% High-school	43.4	46.7	<0.05

% College	7.7	8.5	NS

% Self-reported gingival bleeding	5.1	3.4	<0.05

GDP	0.63	0.70	<0.05

HDI	0.75	0.78	<0.05

UBNI	32	20.7	<0.05


ZMP	Fore-aft	Lateral

Std.	Std.

Open-loop	21.1 mm	14.9 mm

Closed-loop	12.1 mm	14.1 mm

ZMP	Std.	Std.

Open-loop	21.1 mm	14.9 mm

Closed-loop	12.1 mm	14.1 mm


GO Term	Annotation	Abbreviation

GO:0006281	DNA repair	DNA repair

GO:0006284	base-excision repair	BER

GO:0006289	nucleotide-excision repair	NER

GO:0006298	mismatch repair	MMR

GO:0000724	double-strand break repair via homologous recombination	HR

GO:0006303	double-strand break repair via non-homologous end joining	NHEJ

GO Term	on	Abbreviation

GO:0006281	DNA repair	DNA repair

GO:0006284	base-excision repair	BER

GO:0006289	nucleotide-excision repair	NER

GO:0006298	mismatch repair	MMR

GO:0000724	double-strand break repair via homologous recombination	HR

GO:0006303	double-strand break repair via non-homologous end joining	NHEJ


Patient characteristics:	N	%	Median	Range

All MPS I	61

	Gender (male/female)	38/23	62/38

	Phenotype (Hurler/Attenuated)	44/17	69/31

	Age @ Start of treatment (mths)			18	3-364

	Age @ final assessment (mths)			82	0.3-420

HSCT treated Hurler patient characteristics

	Gender (male/female)	30/14

	Age @ Start of treatment (mths)			14	3-30

	Age @ final assessment (mths)			66	11-203

	Interventions

	Therapeutic airway intervention post-HSCT	3	7%	Adenotonsillar surgery: 2 pts (1 had revision). Longterm O2: 1

	Treatments and metabolic characteristics

	No HSCT (1/2/3)	32/8/1	78/20/2

	Source (CB/BM/PBSC/Unknown)	17/15/7/2	41/37/17/5

	Donor (Related/MUD)	15/26	37/63

	IDUA @ 1 year post HSCT	36		30.0	6.3-87.0

	Heterozygote Donors	12		19.7	6.7-49.4

	Matched Unrelated Donors	24		34.6	17.7-87.0

	Pre HSCT DS:CS ratio	20		1.6	0.7-3.4

	DS:CS ratio @ 1 year	32		0.5	0.2-0.8

ERT treated Hurler Patients

	Gender (male/female)	2/1

	Age @ Start of treatment (mths)			85	74-144

	Age @ final assessment (mths)			123	98-148

ERT Treated attenuated patients

	Gender (male/female)	9/8

	Age @ Start of treatment (mths)			60	24-364

	Age @ final assessment (mths)			131	72-420

	Interventions

	Therapeutic airway intervention on ERT	7	41%	CPAP: 5 pts

Adenotonsillar Surgery: 2 pts (1 had revision)

	Metabolic characteristics

	Pre ERT DS:CS ratio	5		1.9	1.1-2.7

	DS:CS ratio @ 1 year	13		0.8	0.4-2.2

Patient characteristics:	N	%	Median	Range

All MPS I	61

	Gender (male/female)	38/23	62/38

	Phenotype (Hurler/Attenuated)	44/17	69/31

	Age @ Start of treatment (mths)			18	3-364

	Age @ final assessment (mths)			82	0.3-420

HSCT treated Hurler patient characteristics

	Gender (male/female)	30/14

	Age @ Start of treatment (mths)			14	3-30

	Age @ final assessment (mths)			66	11-203

	Interventions

	Therapeutic airway intervention post-HSCT	3	7%	Adenotonsillar surgery: 2 pts (1 had revision). Longterm O2: 1

	Treatments and metabolic characteristics

	No HSCT (1/2/3)	32/8/1	78/20/2

	Source (CB/BM/PBSC/Unknown)	17/15/7/2	41/37/17/5

	Donor (Related/MUD)	15/26	37/63

	IDUA @ 1 year post HSCT	36		30.0	6.3-87.0

	Heterozygote Donors	12		19.7	6.7-49.4

	Matched Unrelated Donors	24		34.6	17.7-87.0

	Pre HSCT DS:CS ratio	20		1.6	0.7-3.4

	DS:CS ratio @ 1 year	32		0.5	0.2-0.8

ERT treated Hurler Patients

	Gender (male/female)	2/1

	Age @ Start of treatment (mths)			85	74-144

	Age @ final assessment (mths)			123	98-148

ERT Treated attenuated patients

	Gender (male/female)	9/8

	Age @ Start of treatme			60	24-364

Patient characteristics:	N	%	Median	Range

	nt (mths)

	Age @ final assessment (mths)			131	72-420

	Interventions

	Therapeutic airway intervention on ERT	7	41%	CPAP: 5 pts

Adenotonsillar Surgery: 2 pts (1 had revision)

	Metabolic characteristics

	Pre ERT DS:CS ratio	5		1.9	1.1-2.7

	DS:CS ratio @ 1 year	13		0.8	0.4-2.2


Position	Residue (number of independent origins)

135	I (4), L (A), *T (1), V (2)

154	A (1), *C (1), *F (1), I (A), L (2), *M (1), V (5)


CLOCK genotypes	Non-T2D subjects at baseline (n = 3671)

Cases	Person-y	Incidence ratea	Model 1	Model 2

HR	95 % CI	P value	HR	95 % CI	P value

Dominant model

 CC	130	6088.5	21.4	1.00	(Reference)		1.00	(Reference)

 CG + GG	156	10727.7	14.5	0.68	(0.54–0.86)	0.001	0.69	(0.54–0.87)	0.002


Case	Treatment period (course)	Reason for cessation of therapy

1	4	Originally scheduled

2	8

3	8

4	8

5	4	Changing the treatment

6	2	Severe watering eyes and fatigue

7	8

8	2	Changing the hospital

9	8

10	7	Repeated extension of drug holidays

11	6	Repeated extension of drug holidays

Treatment period (course)	Reason for cessation of therapy

4	Originally scheduled

8

8

8

4	Changing the treatment

2	Severe watering eyes and fatigue

8

2	Changing the hospital

8

7	Repeated extension of drug holidays

6	Repeated extension of drug holidays


Variable	OR	SE	95% CI	p value

Model 1. Knowledge about the modes of transmission and the main preventative measures of HIV (Sample size=244)

Log likelihood=−118.4, χ2=37.67 (6 df), p<0.0001

Physician as source of information about HIV/AIDS	4.34	1.71	2.01-9.42	<0.001

Having had more than one sexual partner and no consistent condom use in the last year	0.33	0.13	0.16-0.7	0.004

Educational level

Middle school or lower	0.34	0.16	0.14-0.84	0.019

Baccalaureate degree/graduate degree*	1.0

Employment status	0.63	0.2	0.33-1.19	0.15

Need of additional information about HIV/AIDS	0.63	0.21	0.33-1.21	0.17

Number of other persons in the household	0.69	0.27	0.32-1.47	0.34

Model 3. Having received the HIV test (Sample size=244)

Log likelihood=−114.71, χ2=20.76 (5 df), p<0.0001

Having visited a physician or having participated in preventive activities about HIV/AIDS	2.67	0.93	1.35-5.29	0.005

Gender	0.42	1.66	0.19-0.91	0.028

Knowledge about the modes of transmission and the main preventative measures of HIV	1.73	0.62	0.85-3.52	0.13

Educational level

Middle school or lower	0.54	0.23	0.23-1.26	0.15

Baccalaureate degree/graduate degree*	1.0

Injecting drugs use in the last year	1.85	0.8	0.79-4.33	0.16

Variable	Coeff	SE	t	p value

Model 2. Fear of contracting HIV/AIDS (Sample size=244)

F(6,237)=6.96, p<0.0001, R2=15%, adjusted R2=12.8%

Perception of personal health status	0.25	0.08	2.94	0.004

Age	−0.04	0.02	−2.48	0.014

Marital status	−0.84	0.41	−2.07	0.04

Need of additional information about HIV/AIDS	0.5	0.33	1.5	0.13

Gender	0.51	0.34	1.5	0.13

Having received the HIV test	0.39	0.39	1.01	0.31

Constant	5.87


Variable	n	%

Official graduation

Soldier	99	60

Corporal	38	23

Sargent	17	10.3

Sublieutenant	2	1.2

Lieutenant	5	3

Capitan	2	1.2

Major	2	1.2

Total	165	100

Operation

Predominantly administrative	28	17

Predominantly operational	137	83

Total	165	100

Years of service

1-10	67	40.6

11-20	34	20.6

21-30	62	37.6

Above 31	2	1.2

Total	165	100

Leisure physical activity level

Low	86	52.1

Moderate	37	22.4

High	24	14.52

Very high	18	10.9

Total	165	100

Coronary risk rating

Risk much lower than average	10	6.1

Risk lower than average	58	35.2

Medium risk	70	42.4

Moderate risk	25	15.2

High risk	2	1.2

Total	165	100

Variable	n	%

High	24	14.52

Very high	18	10.9

Total	165	100

Coronary risk rating

Risk much lower than average	10	6.1

Risk lower than average	58	35.2

Medium risk	70	42.4

Moderate risk	25	15.2

High risk	2	1.2

Total	165	100


Age (years, mean ± SD (median and range))	67.8 ± 13.5 (68, 35-94)

Gender (male/female)	35/26

Eastern Cooperative Oncology Group Performance Status (0/1/2/3)	33/13/12/3

Location (colon/rectum)	32/29

Primary tumor-related obstruction (yes/no)	36/25

Metastasis (n)

 Liver only	20

 Liver and lung	10

 Liver and peritoneum	5

 Extended lymph node only	4

 Peritoneum only	4

 Lung only	1

 Bone only	1

 Lung and bone	1

Treatment (n)

 Chemotherapy only	16

 Surgical intervention + chemotherapy	25

 Surgical intervention only	13

 Best supportive care	7


Test	k-mer size	Promoter Set	Error (Ave ± S.D.)

(g, k)-table	6	small	3.53e-5 ± 1.87e-4

		large	2.65e-5 ± 1.04e-4

	8	small	1.84e-5 ± 6.57e-5

		large	1.16e-5 ± 4.35e-5

ESAsearch		small	1.23e-4 ± 5.96e-4

		large	1.61e-4 ± 7.68e-4

Test	k-mer size	Promoter Set	Error (Ave ± S.D.)

	8	small	1.84e-5 ± 6.57e-5

		large	1.16e-5 ± 4.35e-5

ESAsearch		small	1.23e-4 ± 5.96e-4

		large	1.61e-4 ± 7.68e-4


		CONV (N = 2575)	CAM (N = 6595)

		#	%	95% CI	#	%	95% CI

Physicians	N	78	30		184	70

Patients	Children (N = 1291)	118	9		1173	91

	Adults* (N = 7879)	2457	31		5422	69

	All	2575	28		6595	72

Proportion of female, patients	Children**	72	61	52–70	537	46	43–48

	Adults**	1405	57	54–60	3866	71	70–73

	All*	1477	57	54–61	4403	67	65–68

Mean age, patients	Children	11 years	7 years

	Adults	51 years	49 years

	All	49 years	41 years

Physicians	N

Patients	Children (N = 1291)

	Adults* (N = 7879)

	All

Proportion of female, patients	Children**

	Adults**

	All*

Mean age, patients	Children

	Adults

	All


Position	Orientation	Distance/Å

B	U	3.40

C	U	3.49

T	U	3.66

B	D	3.46

C	D	3.45

T	D	3.45


Characteristics	Patients (Percentages)

Gender:

 Male	49 (57)

 Female	37 (43)

Median Age:	63

Surgery:

 Biopsy	7 (8)

 STR	32 (37)

 GTR	47 (55)

Adjuvant treatment:

 Long course adjuvant RT/TMZ	65 (75)

 Hypofractionated RT/TMZ	4 (5)

 Hypofractionated RT	17 (20)

 TMZ alone	0 (0)

Radiotherapy dose:

 60Gy	65 (76)

 40Gy	21 (24)

Re-resection rates:

 No further craniotomy	70 (81)

 Re-resection	16 (19)

Characteristics	Patients (Percentages)

40Gy	21 (24)

Re-resection rates:

No further craniotomy	70 (81)

Re-resection	16 (19)


Parameter	Mean ± SD	Range

Urinary sTNF-R55 (ng/μmol creatinine)	29.2 ± 20.1	1.94–117

Urinary sTNF-R55 (pg/ml)	277 ± 183	52.0–861

Urinary sTNF-R55 (ng/h)	16.7 ± 11.5	0.94–81.1

Urinary protein (mg/μmol creatinine)	3.20 ± 2.25	0.08–14.5

Urinary protein (mg/dl)	3.48 ± 2.58	0.10–10.0

Urinary protein (mg/h)	1.76 ± 1.09	0.07–6.38

Oral ulceration (%)	0.59 ± 2.79	0.00–19.9

Facial rash (%)	2.67 ± 5.60	0.00–22.0

Body temperature (°C)	36.7 ± 0.25	36.1–37.4

Weakness (%)	7.77 ± 5.86	0.00–38.0

Fatigue (%)	35.2 ± 17.2	6.00–77.0

Joint pain (%)	20.2 ± 11.5	5.00–54.0

Parameter	Mean ± SD	Range

Urinary sTNF-R55 (ng/μmol creatinine)	29.2 ± 20.1	1.94–117

Urinary sTNF-R55 (pg/ml)	277 ± 183	52.0–861

Urinary sTNF-R55 (ng/h)	16.7 ± 11.5	0.94–81.1

Urinary protein (mg/μmol creatinine)	3.20 ± 2.25	0.08–14.5

Urinary protein (mg/dl)	3.48 ± 2.58	0.10–10.0

Urinary protein (mg/h)	1.76 ± 1.09	0.07–6.38

Oral ulceration (%)	0.59 ± 2.79	0.00–19.9

Facial rash (%)	2.67 ± 5.60	0.00–22.0

Body temperature (°C)	36.7 ± 0.25	36.1–37.4

Weakness (%)	7.77 ± 5.86	0.00–38.0

F	35.2 	6.00–77.0

Parameter	Mean ± SD	Range

atigue (%)	± 17.2

Joint pain (%)	20.2 ± 11.5	5.00–54.0


Gene	size	Sense primer	Antisense primer

Ehvps2	741	5′-GCGGATCCATGTCAAGGTTATTC-3′	5′-CCGTCGACTTAAAGATTGGCTATTCT

			TGAAACAATATCATCTTCATCTTC-3′

Ehvps20	621	5′-GCGGATCCATGTTAAATCGATTCA-3′	5′-CCGTCGACTTTAAATTGCAAATTTTTT

			GCTATCTGGTT-3′

Ehvps20 (1-173)	522	5′-CCGGATCCATGTTAAATCGATTCA-3′	5′-CGTCGACTTAAATATCTCCTTCAAACA

			TTGAAT-3′

Ehvps24	618	5′-GCGGATCCATGGGCAACCTTAAT	5′-CCGTCGACTTAAAAGGTTTCTATTACA

		AGCCAAACAGTAGATAATAG-3′	ATATTTTGTTTAGATATTAACATTCACTT-3′

Ehvps32 (1-165)	495	5′-CCCCGGATCCATGTCTTGGTTCA	5′-CCCCGTCGACTTATTCTTGTTCATCA

		GAAGAAATACTAC-3′	AGAACTTGATCTTCTAAT-3′

Gene	size	Sense primer	Antisense primer

Ehvps32 (1-165)	495	5′-CCCCGGATCCATGTCTTGGTTCA	5′-CCCCGTCGACTTATTCTTGTTCATCA

		GAAGAAATACTAC-3′	AGAACTTGATCTTCTAAT-3′


Process mode	Sugar	Strain	Time	CDW	Sugar consumed	3HB	HAc	mean qS total	mean q3HB	Y3HB/HAc	Y3HB/CDW	Y3HB/Sugar

			(h)	(g L−1)	(g L−1)	(g L−1)	(g L−1)	(g g−1 h−1)	(mg g−1 h−1)	(g g−1)	(g g−1)	(g g−1)

Batch	Glc	AF1000	5.5	4.18	8.90	0.51	0.96	1.0	68	0.54	0.12	0.06

Batch	Glc + Xyl + Ara	PPA652ara	7.3	4.88	9.65	0.31	0.00	0.7	25	→ ∞	0.06	0.03

N-depletion	Glc + Xyl + Ara	AF1000	16.0	0.27	2.73	0.64	0.48	0.2	29	1.33	2.37	0.23


Probe set	Microarray	Probe subset	T0	T1	T2	T4	T8	T12

PrV	SLA/PrV	Probes homologous to a single transcript	0	3	7	18	26	30

		Total	0	3	13	34	52	58

Pig	SLA/PrV	up-regulated SLA/Immune probes	0	0	0	1	4	3

		down regulated SLA/Immune probes	0	0	0	11	18	13

		up-regulated random probes	1	0	2	4	15	11

		down-regulated random probes	0	0	0	20	70	80

		Total	1	0	2	36	107	107

	Qiagen- NRSP8	up-regulated probes	ND*	27	134	1262	3184	ND*

		down-regulated probes	ND*	4	47	1494	3509	ND*

		Total	ND*	31	181	2756	6693	ND*

Probe set	Microarray	Probe subset	T0

PrV	SLA/PrV	Probes homologous to a single transcript	0

		Total	0

Pig	SLA/PrV	up-regulated SLA/Immune probes	0

		down regulated SLA/Immune probes	0

		up-regulated random probes	1

		down-regulated random probes	0

		Total	1

	Qiagen- NRSP8	up-regulated probes	ND*

		down-regulated probes	ND*

		Total	ND*


	Morphed	Non-morphed

Same identity	Not associated during training	Associated during training

Different identity	Associated during training	Not associated during training


MOTHERS	INFANTS

	N	θw	θc			θw	θc

M		0		Infant 	12	0	0.033


	Phe/protein goals	Formula goals	Healthy food choices

Precontemplation	1	–	–

Contemplation	6	–	5

Preparation	5	5	5

Action	5	6	10

Maintenance	14	20	11

Precontemplation

Contemplation

Preparation

Action

Maintenance

Phe/protein goals	Formula goals	Healthy food choices

1	–	–

6	–	5

5	5	5

5	6	10

14	20	11


Variable	n	%

Gender

 Female	1371	62.1

 Male	836	37.9

Age

 ≤16 years	1259	57.3

 ≥17 years	940	42.7

Socioeconomic status

 High (A1, A2, B1, B2)	517	23.7

 Intermediate (C1, C2)	1383	63.4

 Low (“D” and “E”)	280	12.8

Violent behavior

 Yes	363	16.5

 No	1842	83.5

Cigarette smoking

 Yes	146	6.6

 No	2051	93.4

Alcohol consumption

 Yes	844	38.5

 No	1350	61.5

Marijuana consumption

 Yes	53	2.4

 No	2140	97.6

Body shape satisfaction

 Satisfied	1314	59.9

 Dissatisfied	879	40.1

Physical activity

 Low levels	1945	89.2

 Active	236	10.8

Suicide ideation

 Yes	307	14.0

 No	1889	86.0

Suicide plan

 Yes	208	9.5

 No	1992	90.5

Suicide attempt

 Yes	131	5.9

 No	94.1	94.1


Baseline characteristic variables	Intervention group (n = 70)	Control group (n = 72)	Meaningful level (P value)

Age (mean ± SD)	32.04 ± 5.901	29.77 ± 5.21	0.017

Number of previous pregnancies (mean ± SD)	3.04 ± 1.13	2.92 ± .900	0.463

Weeks of pregnancy(mean ± SD)	14.39 ± 3.12	14.39 ± 2.69	0.997

Systolic blood pressure(mm Hg; mean ± SD)	115.87 ± 14.52	114.51 ± 7.27	0.028

Diastolic blood pressure(mm Hg; mean ± SD)	74.28 ± 4.95	74.31 ± 6.40	0.975

Uterine ↓ cm(mean ± SD)	14.58 ± 3.50	14.28 ± 3.26	0.597

24 h proteinuria (mg/cc;mean ± SD)	132.22/1844.91 ± 61.447	154.94/1958.53 ± 53.376	0.023


Mean± SD	Poor collateral	Good collateral	P value

Number (%)	(n = 122)	(n = 80)

Number of diseased vessels	2.1 ± 0.9	2.6 ± 0.6	<0.001

Significant CAD, n (%)

1 vessel disease (%)	47 (38.5)	12 (15.0)

2 vessel disease (%)	41 (33.6)	21 (26.3)	<0.001

3 vessel disease (%)	34 (27.9)	47 (58.8)

Diffuse score of CAD	3.01 ± 1.75	4.03 ± 1.83	<0.001

1 vessel disease	1.25 ± 0.67	1.42 ± 0.66

2 vessel disease	2.72 ± 0.86	2.84 ± 0.99

3 vessel disease	4.41 ± 1.43	4.84 ± 1.63

Mean± SD	Poor collateral

Number (%)	(n = 122)

Number of diseased vessels	2.1 ± 0.9

Significant CAD, n (%)

1 vessel disease (%)	47 (38.5)

2 vessel disease (%)	41 (33.6)

3 vessel disease (%)	34 (27.9)

Diffuse score of CAD	3.01 ± 1.75

1 vessel disease	1.25 ± 0.67

2 vessel disease	2.72 ± 0.86

3 vessel disease	4.41 ± 1.43


Gene ID	Gene	Regulation	Computational matching of regulatory consensus	Position of DNA fragment used §

			Position§	Sequence	Score	LacZ	Footprinting

YPO1222	ompC	+	R-191...-169	AAACAGTGAGTTATAGCACATAT	12.3	-379...+130	-281...-26

YPO1411	ompF	+	D-131...-109	ACTTTGTGACTTAGATCGAATTT	10.73	-328...+143	-237...-4

YPO2506	ompX	-	D-156...-134	AGTATGTGACCTCCATCACCCAA	11.68	-374...+123	-321...+4

YPO0136	ompR	NO	-	-	0	-409...+83	-409...+83

YPO0175	crp	NO	R+235...+257	GAACTCTGAGCCCTGTTAAGTTA	1.44	-147...+344	-147...+344


Exon	Name	Target	Amplicon size	Sequence (5’–3’)

18	18 FP	G719A/S/C	112 bp	CAGGAAACAGCTATGACCTGGAGCCTCTTACACCCAGT

18 RP			ACCGTGCCGAACGCACCGGA

18 LNA			GAGCCCAGC

19	19 FP	Deletions	176 bp	GTTAAAATTCCCGTCGCTATCA

19 RP			TGTAAAACGACGGCCAGTTGTGGAGATGAGCAGGGTCT

19 LNA			CAAGGAATTAAGA

20	20 FP	Insertions	161 bp	GAAGCCTACGTGATGGCCA

20 RP			CAGGAAACAGCTATGACCAGCAGGTACTGGGAGCCAAT

20 LNA			CAGCGTGGACA

-	M13-tag 1	For Sanger sequencing	-	TGTAAAACGACGGCCAGT

-	M13-tag 2	For Sanger sequencing	-	CAGGAAACAGCTATGACC

Exon	Name	Target	Amplicon size	Sequence (5’–3’)

19	19 FP	Deletions	176 bp	GTTAAAATTCCCGTCGCTATCA

19 RP			TGTAAAACGACGGCCAGTTGTGGAGATGAGCAGGGTCT

19 LNA			CAAGGAATTAAGA

20	20 FP	Insertions	161 bp	GAAGCCTACGTGATGGCCA

20 RP			CAGGAAACAGCTATGACCAGCAGGTACTGGGAGCCAAT

20 LNA			CAGCGTGGACA

-	M13-tag 1	For Sanger sequencing	-	TGTAAAACGACGGCCAGT

-	M13-tag 2	For Sanger sequencing	-	CAGGAAACAGCTATGACC


Covariates	dfAIC	dfAICc

DI	14.99	14.99

Size	10.98	10.63

LNI	2.01	1.50


	P value of the Wilcoxon signed-rank test

DSSs	PRM (Degree)	LPDS	BRDS	FUDS	LBDS	LFDS	BFDS

LPDS	4.02 ± 1.84

BRDS	39.70 ± 4.60	<0.001

FUDS	0.93 ± 1.06	<0.001	<0.001

L	31.44 ± 5.10	<0.0	<0.001	<0.


Key inclusion criteria	Key exclusion criteria

- Male or female patients ≥18 years old.	- Patients with a history of acute rejection classified > BANFF II, chronic active antibody-mediated rejection or chronic T-cell-mediated rejection.

- Recipients of deceased or living kidney transplants.	- Patients with an EC-MPS dose of <720 mg/d (MMF <1000 mg/d) and MPA-AUC <30 mg*h/L.

- Time after the last renal transplantation at least six months.	- Patients with symptoms of significant somatic or mental illness. Inability to cooperate or communicate with the investigator, who are unlikely to comply with the study requirements, or who are unable to give informed consent.

- Stable renal allograft function, defined as S-creatinine ≤3.5 mg/dL and Δ S-creatinine ≤30% during the last three months.	- Females of childbearing potential who are planning to become pregnant, who are pregnant or lactating, and/or who are unwilling to use effective means of contraception, unless

- Patients who are willing and able to participate in the study and from whom written informed consent has been obtained.	a. their career, lifestyle, or sexual orientation precludes intercourse with a male partner,orb. their partners have been sterilised by vasectomy or other means

	- Evidence of drug or alcohol abuse

	- Patients actively taking part in an interventional trial

Key inclusion criteria

- Male or female patients ≥18 years old.

- Recipients of deceased or living kidney transplants.

- Time after the last renal transplantation at least six months.

- Stable renal allograft function, defined as S-creatinine ≤3.5 mg/dL and Δ S-creatinine ≤30% during the last three months.

- Patients who are willing and able to participate in the study and from whom written informed consent has been obtained.

Key exclusion criteria

- Patients with a history of acute rejection classified > BANFF II, chronic active antibody-mediated rejection or chronic T-cell-mediated rejection.

- Patients with an EC-MPS dose of <720 mg/d (MMF <1000 mg/d) and MPA-AUC <30 mg*h/L.

- Patients with symptoms of significant somatic or mental illness. Inability to cooperate or communicate with the investigator, who are unlikely to comply with the study requirements, or who are unable to give informed consent.

- Females of childbearing potential who are planning to become pregnant, who are pregnant or lactating, and/or who are unwilling to use effective means of contraception, unless

a. their career, lifestyle, or sexual orientation precludes intercourse with a male partner,orb. their partners have been sterilised by vasectomy or other means

- Evidence of drug or alcohol abuse

- Patients actively taking part in an interventional trial


ORF	Gene Symbol	EC	Enzyme	Evidence

a) Intersection of our predictions with the experimental screen

STM0123	murE	6.3.2.13	UDP-N-acetylmuramoylalanyl-D-glutamate-2,6-diaminopimelate ligase	**

STM0128	murG	2.4.1.227	N-acetylglucosaminyl transferase	*

STM0129	murC	6.3.2.8	UDP-N-acetylmuramate-L-alanine ligase	**

STM0154	lpdA	1.8.1.4	Dihydrolipoamide dehydrogenase

STM0218	pyrH	2.7.4.22	Uridylate kinase	*

STM0221	uppS	2.5.1.31	Undecaprenyl pyrophosphate synthase	**

STM0222	cdsA	2.7.7.41	CDP-diglyceride synthase

STM0228	lpxA	2.3.1.129	UDP-N-acetylglucosamine acyltransferase

STM0232	accA	6.4.1.2	Acetyl-CoA carboxylase	**

STM0489	hemH	4.99.1.1	Ferrochelatase	*

STM0535	lpxH		UDP-2,3-diacylglucosamine hydrolase

STM0542	folD	1.5.1.5, 3.5.4.9	Bifunctional 5,10-methylene-tetrahydrofolate dehydrogenase

STM0988	kdsB	2.7.7.38	CTP:CMP-KDO cytidylyltransferase	*

STM1194	fabD	2.3.1.39	Acyl carrier protein S-malonyltransferase	*

STM1195	fabG	1.1.1.100	3-ketoacyl-(acyl-carrier-protein) reductase	**

STM1200	tmk	2.7.4.9	Thymidylate kinase

STM1700	fabI	1.3.1.10	Enoyl-(acyl carrier protein) reductase

STM2483	dapE	3.5.1.18	Succinyl-diaminopimelate desuccinylase

STM2652	pssA	2.7.8.8	Phosphatidylserine synthase	*

STM3090	metK	2.5.1.6

STM3415	rpoA	2.7.7.6	DNA-directed RNA polymerase subunit alpha

STM3724	kdtA		3-deoxy-D-manno-octulosonic-acid transferase	*

STM3730	dfp	4.1.1.36	Pantothenate kinase	**

STM3912	rep	3.6.1.-	ATP-dependent DNA helicase Rep	*

STM3978	yigC		3-octaprenyl-4-hydroxybenzoate decarboxylase

STM4153	rpoB	2.7.7.6	DNA-directed RNA polymerase subunit beta	*

STM4154	rpoC	2.7.7.6	DNA-directed RNA polymerase subunit beta'

b) Predictions for the non-mevalonate pathway

STM0049	ispH, lytB	1.17.1.2	4-hydroxy-3-methylbut-2-enyl diphosphate reductase	*

STM0220	dxr	1.1.1.267	1-deoxy-D-xylulose 5-phosphate reductoisomerase	*

STM0422	dxs	2.2.1.7	1-deoxy-D-xylulose-5-phosphate synthase	**

STM0423	ispA	2.5.1.10	geranyltranstransferase	*

STM1779	ispE, ipk	2.7.1.149	4-diphosphocytidyl-2-C-methyl-D-erythritol kinase	**

STM2523	ispG, gcpE	1.17.7.1	4-hydroxy-3-methylbut-2-en-1-yl diphosphate synthase	*

STM2929	ispF	4.6.1.12	2-C-methyl-D-erythritol 2,4-cyclodiphosphate synthase	*

STM2930	ispD	2.7.7.60	2-C-methyl-D-erythritol 4-phosphate cytidylyltransferase	*

ORF	Gene Symbol	EC	Enzyme	Evidence

STM4153	rpoB	2.7.7.6	DNA-directed RNA polymerase subunit beta	*

STM4154	rpoC	2.7.7.6	DNA-directed RNA polymerase subunit beta'

b) Predictions for the non-mevalonate pathway

STM0049	ispH, lytB	1.17.1.2	4-hydroxy-3-methylbut-2-enyl diphosphate reductase	*

STM0220	dxr	1.1.1.267	1-deoxy-D-xylulose 5-phosphate reductoisomerase	*

STM0422	dxs	2.2.1.7	1-deoxy-D-xylulose-5-phosphate synthase	**

STM0423	ispA	2.5.1.10	geranyltranstransferase	*

STM1779	ispE, ipk	2.7.1.149	4-diphosphocytidyl-2-C-methyl-D-erythritol kinase	**

STM2523	ispG, gcpE	1.17.7.1	4-hydroxy-3-methylbut-2-en-1-yl diphosphate synthase	*

STM2929	ispF	4.6.1.12	2-C-methyl-D-erythritol 2,4-cyclodiphosphate synthase	*

STM2930	ispD	2.7.7.60	2-C-methyl-D-erythritol 4-phosphate cytidylyltransferase	*


Species	FTa	FTb	FTc	MFT	TFL1	BFT	Total

A. duranensis	3	4	1	2	2	1	13

A. ipaensis	4	4	1	2	3	1	15

C. cajan	2	2	0	1	3	1	9

C. arietinum	3	1	1	1	5	1	12

G. max	4	4	2	1	5	2	18

L. japonicus	1	2	0	1	2	0	6

L. angustifolius	2	0	2	3	4	1	12

M. truncatula	3	2	1	1	3	1	11

P. vulgaris	2	2	1	1	3	1	10

V. radiata	2	4	1	1	3	1	12

Total	26	25	10	14	33	10	118

Species	FTa	FTb	FTc	MFT	TFL1	BFT	Total

L. angustifolius	2	0	2	3	4	1	12

M. truncatula	3	2	1	1	3	1	11

P. vulgaris	2	2	1	1	3	1	10

V. radiata	2	4	1	1	3	1	12

Total	26	25	10	14	33	10	118


 	Defecation: all records

Variable	Pooled	Pooled	Means (n > 5)	Means (n > 5)

Data type	angular	axial	angular	axial

Number of observations	1,893	1,893	49	49

Mean vector (μ)	133°	157°/337°	80°	148°/328°

Length of mean vector (r)	0.013	0.052	0.043	0.209

Circular standard deviation	169°	70°	144°	51°

95% Confidence interval (-/+) for μ	-	-	-	121°-174°

99% Confidence interval (-/+) for μ	-	-	-	112°-183°

Rayleigh test (Z)	0.307	5.203	0.091	2.143

Rayleigh test (p)	0.736	0.006	0.914	0.117

	Defecation: all records

Variable	Pooled	Pooled	Means (n > 5)

Data type	angular	axial	angular

Number of observations	1,893	1,893	49

Mean vector (μ)	133°	157°/337°	80°

Length of mean vector (r)	0.013	0.052	0.043

Circular standard deviation	169°	70°	144°

95% Confidence interval (-/+) for μ	-	-	-

99% Confidence interval (-/+) for μ	-	-	-

Rayleigh test (Z)	0.307	5.203	0.091

Rayleigh test (p)	0.736	0.006	0.914


PS:NRS	ASIA	Ambulatory function score	RR	LR (m)	Follow-up (m)	Cause of death

2-3	E		PR	13	69	MM

0-1	C		PR	8	11	MM

5-6	C		SD	39	41	MM

1-2	D		PR	32	32	MM

0-1	E		CR	34	36	MM

1-2	D		PR	19	19	MM

0-1	D		CR	36	36	S

2	E		PR	35	35	S

0-1	E		PR	21	21	S

1-2	E		PR	4	4	MM

2	E		PR	17	17	S

0	E		PR	3	3	S

0	E		SD	3	3	S

1	E		PR	12	12	S

3	D		PR	11	11	S

2	D		SD	2	2	S

0-1	E		SD	14	20	LR


Phase	Activity	Setting	Duration

1. Open focus group discussion	Firstly, informal conversation and ice-breaking activities were used to create a relaxing environment. Then a discussion was conducted to identify barriers that influence children’s recess play. Questions used were:	Classroom/meeting room at the school	30 minutes

• What are your experiences around recess?

• What do you do during recess?

• Who are you playing with?

• Who initiates play?

• Is there something you want to do in recess that you cannot or may not do? What was this?

• What do you think about your schoolyard?

• Can you explain what physical activity is?

• Do you like being physically active? Why/why not?

• What influences your physical activity during recess?

2. Go-along interview	The children pointed out where they usually played during recess, the activity they played and who they played with. A Google Earth aeria photograph of the schoolyard was used as a tool (by the moderator), to indicate where different activities took place.	Shared indoor and outdoor areas at the school	20 minutes

3. Post-it note activity	An open brainstorm to identify significant barriers to engaging in physical activity during recess. The groups were told to write down all the barriers that they could think of on post-it notes.	Classroom/meeting room. Gender separated groups	10 minutes

Phase	Activity	Setting	Duration

1. Open focus group discussion	• Do you like being physically active? Why/why not?	Classroom/meeting room at the school	30 minutes

• What influences your physical activity during recess?

2. Go-along interview	The children pointed out where they usually played during recess, the activity they played and who they played with. A Google Earth aeria photograph of the schoolyard was used as a tool (by the moderator), to indicate where different activities took place.	Shared indoor and outdoor areas at the school	20 minutes

3. Post-it note activity	An open brainstorm to identify significant barriers to engaging in physical activity during recess. The groups were told to write down all the barriers that they could think of on post-it notes.	Classroom/meeting room. Gender separated groups	10 minutes


Response	Fraction	Acid/alkali	pH	T	t	pH·T	pH·pH	T·t

Glucose	Solid	Acidic		x		x	x	-

	Liquid	Acidic	-					-

Xylose	Solid	Acidic	x	x		x	x

	Liquid	Acidic	x

Lignin	Solid	Acidic						x

Glucose	Solid	Alkaline	x			x	x

	Liquid	Alkaline	x	x				x

Xylose	Solid	Alkaline	x		-		x

	Liquid	Alkaline	x		x	x	x

Lignin	Solid	Alkaline	x			x	x

Response	Fraction	Acid/alkali	pH

Glucose	Solid	Acidic

	Liquid	Acidic	-

Xylose	Solid	Acidic	x

	Liquid	Acidic	x

Lignin	Solid	Acidic

Glucose	Solid	Alkaline	x

	Liquid	Alkaline	x

Xylose	Solid	Alkaline	x

	Liquid	Alkaline	x

Lignin	Solid	Alkaline	x

T	t	pH·T	pH·pH	T·t

x		x	x	-

				-

x		x	x

				x

		x	x

x				x

	-		x

	x	x	x

		x	x


Case no.	Sex	Age (y)	Profession	Eye	Risk Factor	Disease course	Initial diagnosis

P1	Female	55	Actress	Left	Eye exposure to cosmetics	4 m	AK

P2	Male	44	Fisherman	Left	Eye exposure to fish pond water	20d	AK

P3	Male	60	Farmer	Right	Mosquito entering into the eye	2 m	FK

P4	Female	23	Clerk	Right	Wearing contact lenses	1 m	HSK

P5	Male	52	Farmer	Left	Hit with an iron wire	2 m	FK

P6	Male	49	Farmer	Left	Eye exposed to paddy field water	45d	AK

P7	Female	59	Farmer	Right	Winged insect in the eye	1 m	AK

P8	Male	39	Upfitter	Right	Eye exposed to cement	2 m	FK

P9	Male	28	Fisherman	Left	Unclear	40d	HSK

P10	Male	37	Farmer	Right	Unclear	1 m	BK

P11	Male	19	Worker	Right	Eye exposed to foul water	1 m	AK

P12	Male	63	Farmer	Left	Injured by a stick	2 m	FK

P13	Male	37	Farmer	Right	Injured by a stick	1.5 m	FK

P14	Female	39	Farmer	Left	Injured by a stick	3 m	FK

P15	Female	30	Worker	Right	Injured by a pencil	2 m	FK


Statistics	PIS_3	PIS_4

Fluidigm2PURC	reduce_amplicons	Fluidigm2PURC	reduce_amplicons

Consensus

Alignment length (bp)	395	415	403	418

Percent gaps	27.9	30.0	1.9	4.4

Parsimony informative sites	19	19	11	10

Unknown ploidy/occurrence

No. of haplotypes	18	5	14	6

Alignment length (bp)	395	403	403	424

Percent gaps	16.2	48.9	2.7	7.1

Parsimony informative sites	48	11	43	10

Known ploidy

No. of haplotypes	57	—	43	—

Alignment length (bp)	395	—	403	—

Percent gaps	10.3	—	2.6	—

Parsimony informative sites	81	—	62	—

Statistics	PIS_3

Fluidigm2PURC

Consensus

Alignment length (bp)	395

Percent gaps	27.9

Parsimony informative sites	19

Unknown ploidy/occurrence

No. of haplotypes	18

Alignment length (bp)	395

Percent gaps	16.2

Parsimony informative sites	48

Known ploidy

No. of haplotypes	57

Alignment length (bp)	395

Percent gaps	10.3

Parsimony informative sites	81

PIS_3	PIS_4

reduce_amplicons	Fluidigm2PURC	reduce_amplicons

Consensus

415	403	418

30.0	1.9	4.4

19	11	10

Unknown ploidy/occurrence

5	14	6

403	403	424

48.9	2.7	7.1

11	43	10

Known ploidy

—	43	—

—	403	—

—	2.6	—

—	62	—


	Would more or better testing have produced a more effective intervention?

Was the intervention tested?1	Yes	No	Unclear	Totals

Yes – extensively	4	11	1	16

Yes – to some degree	5	11	2	18

No	4	4	0	8

Totals	13	26	3	42

	Was the test phase mentioned in the published article?2

Was the intervention tested?1	Yes	No		Totals

Yes – extensively	10	6		16

Yes – to some degree	7	11		18

No	-	8		8

Totals	17	25		42

	Would more or better testing have produced a more effective intervention?

Was the intervention tested?1	Yes	No	Unclear	Totals

Was the intervention tested?1	Yes	No		Totals

Yes – extensively	10	6		16

Yes – to some degree	7	11		18

No	-	8		8

Totals	17	25		42


Knowledge items	Mean current knowledge score (1–5)	Mean desired knowledge score (1–5)	Gapa

Dosing and creating effective treatment plans for patients using CTP	1.63	4.10	2.60

Health Canada's MMPR	1.88	4.20	2.43

Similarities and differences between dried cannabis, other forms of cannabis products, and prescription cannabinoid medications	1.83	4.14	2.41

Laws and regulations surrounding CTP	2.06	4.21	2.29

Mechanism of action of cannabis/endocannabinoid system	2.15	4.16	2.24

Safety, warning signs and precautions for patients using CTP	2.21	4.22	2.18

Alternative routes of administration of CTP	2.10	4.13	2.11

Potential risks of using CTP	2.39	4.20	1.96

Potential uses of CTP	2.57	4.13	1.79

Knowledge items	Mean current knowledge score (1–5)	Mean desired knowledge score (1–5)	Gapa

Dosing and creating effective treatment plans for patients using CTP	1.63	4.10	2.60

Health Canada's MMPR	1.88	4.20	2.43

Similarities and differences between dried cannabis, other forms of cannabis products, and prescription cannabinoid medications	1.83	4.14	2.41

Laws and regulations surrounding CTP	2.06	4.21	2.29

Mechanism of action of cannabis/endocannabinoid system	2.15	4.16	2.24

Safety, warnin	2.2	4.2	2.1

g signs and precautions for patients using CTP	1	2	8

Alternative routes of administration of CTP	2.10	4.13	2.11

Potential risks of using CTP	2.39	4.20	1.96

Potential uses of CTP	2.57	4.13	1.79


	Tracheostomy	No tracheostomy	Standardized differences of mean

Number (%) or mean ± sd	Number (%) or mean ± sd

Number	267	267

Age	58.4 ± 16.6	58.9 ± 17.9	0.03

Sex (male)	171 (64.0)	171 (64.0)	0.00

BMI	27.9 ± 7.8	27.9 ± 15.0	0.00

Geographic area

 European countries with high income	174 (64.2)	172 (64.4)	0.02

 Non-European countries with high income	49 (18.4)	48 (18.0)	0.01

 Countries with middle income	44 (16.5)	47 (17.6)	0.03

Type of admission

 Medical	178 (66.7)	183 (68.5)	0.04

 Surgical	52 (19.5)	48 (18.0)	0.04

 Elective	19 (7.1)	21 (7.9)	0.03

 Trauma	18 (6.7)	15 (5.6)	0.05

Comorbidities

 COPD or home ventilation	60 (22.5)	65 (24.3)	0.04

 Diabetes mellitus	64 (23.9)	64 (23.9)	0.00

 Chronic renal failure	27 (10.1)	23 (8.6)	0.05

 Immunosuppression or active or hematologic neoplasm	66 (24.7)	62 (23.3)	0.04

 Heart failure (NYHA classes III-IV)	19 (7.1)	22 (8.2)	0.04

 Chronic liver failure (Child-Pugh Class C)	2 (0.7)	2 (0.7)	0.00

 Cause of AHRF - pneumonia	186 (69.7)	195 (73.0)	0.07

ARDS risk factor

 No risk factor	17 (6.4)	17 (6.4)	0.00

 Only indirect risks factor	45 (16.9)	39 (14.6)	0.06

 Only direct risk factors	168 (62.9)	173 (65.0)	0.04

 Both risk factors	37 (13.9)	38 (14.2)	0.01

ECMO use	19 (7.1)	16 (6.0)	0.05

Arterial gas

 pH	7.4 ± 0.1	7.4 ± 0.1	0.07

 P/F ratio (mmHg)	204.1 ± 86.5	199.1 ± 63.7	0.07

 PaCO2 (mmHg)	44.4 ± 13.9	44.2 ± 14.1	0.01

Non-respiratory SOFA score adjusted for missing values,	5.1 ± 3.4	5.1 ± 3.6	0.00

	Tracheostomy	No tracheostomy	Standardized differences of mean

Number (%) or mean ± sd	Number (%) or mean ± sd

Chronic liver failure (Child-Pugh Class C)	2 (0.7)	2 (0.7)	0.00

Cause of AHRF - pneumonia	186 (69.7)	195 (73.0)	0.07

ARDS risk factor

No risk factor	17 (6.4)	17 (6.4)	0.00

Only indirect risks factor	45 (16.9)	39 (14.6)	0.06

Only direct risk factors	168 (62.9)	173 (65.0)	0.04

Both risk factors	37 (13.9)	38 (14.2)	0.01

ECMO use	19 (7.1)	16 (6.0)	0.05

Arterial gas

pH	7.4 ± 0.1	7.4 ± 0.1	0.07

P/F ratio (mmHg)	204.1 ± 86.5	199.1 ± 63.7	0.07

PaCO2 (mmHg)	44.4 ± 13.9	44.2 ± 14.1	0.01

Non-respiratory SOFA score adjusted for missing values,	5.1 ± 3.4	5.1 ± 3.6	0.00


Study	Diagnostic variable	Comparison	Sensitivity (%)	Specificity (%)	PPV (%)	NPV (%)

Casellini (34)	DPN	NIS-LL	78	92	74	93

Smith (9)	Distal symmetric polyneuropathy	UENS	77	67	59	83

Yajnik (37)	DPN	VPT	73	62	N/A	N/A

Eranki (41)	DPN	VPT	82	55	N/A	N/A

Calvet (39)	CAN – diabetes	CARTs	83	63	N/A	N/A

Ozaki (42)	Diabetic kidney disease	eGFR, ACR	94	78	81	93

Study	Diagnostic variable	Comparison	Sensitivity (%)	Specificity (%)	PPV (%)

Casellini (34)	DPN	NIS-LL	78	92	74

Smith (9)	Distal symmetric polyneuropathy	UENS	77	67	59

Yajnik (37)	DPN	VPT	73	62	N/A

Eranki (41)	DPN	VPT	82	55	N/A

Calvet (39)	CAN – diabetes	CARTs	83	63	N/A

Ozaki (42)	Diabetic kidney disease	eGFR, ACR	94	78	81


 	Meeting days	Non-meeting days	P

Whole arrests

 1-month survival, % (n/N)	3.8 (774/20 143)	3.8 (1477/38 859)

Crude OR (95% CI)	1.01 (0.93–1.11)	Reference	0.802

Adjusted OR (95% CI)	1.01 (0.92–1.11)	Reference	0.799

 Favorable neurologic outcome, % (n/N)	1.6 (324/20 142)	1.5 (596/38 855)

Crude OR (95% CI)	1.05 (0.92–1.08)	Reference	0.488

Adjusted OR (95% CI)	1.02 (0.88–1.19)	Reference	0.757

Bystander-witnessed VF arrests with cardiac origin

 1-month survival, % (n/N)	28.9 (275/951)	26.5 (481/1814)

Crude OR (95% CI)	1.12 (0.94–1.35)	Reference	0.179

Adjusted OR (95% CI)	1.10 (0.92–1.33)	Reference	0.297

 Favorable neurologic outcome, % (n/N)	19.1 (182/951)	17.9 (324/1813)

Crude OR (95% CI)	1.09 (0.89–1.33)	Reference	0.413

Adjusted OR (95% CI)	1.04 (0.83–1.29)	Reference	0.750


	Point estimate	SE (boot)	Bootstrapping BC 95 % CI

Lower	Upper

Visiting STI services regularly

 Subjective norms	−0.00	0.02	−0.04	0.04

 Perceived behavioral control	0.08	0.03	0.04	0.15a

Adherence to STI treatment

 Subjective norms	0.13	0.11	0.01	0.46a

 Perceived behavioral control	0.29	0.17	0.10	0.63a

Taking an HIV test

 Subjective norms	0.03	0.03	−0.01	0.09

 Perceived behavioral control	0.03	0.02	0.01	0.07a

Picking up the result of HIV test

 Subjective norms	−0.01	0.02	−0.05	0.02

 Perceived behavioral control	0.13	0.04	0.06	0.22a

	Point estimate	SE (boot)	Bootstrapping BC 95 % CI

Lower

Visiting STI services regularly

Subjective norms	−0.00	0.02	−0.04

Perceived behavioral control	0.08	0.03	0.04

Adherence to STI treatment

Subjective norms	0.13	0.11	0.01

Perceived behavioral control	0.29	0.17	0.10

Taking an HIV test

Subjective norms	0.03	0.03	−0.01

Perceived behavioral control	0.03	0.02	0.01

Picking up the result of HIV test

Subjective norms	−0.01	0.02	−0.05

Perceived behavioral control	0.13	0.04	0.06

Bootstrapping BC 95 % CI

Upper

Visiting STI services regularly

0.04

0.15a

Adherence to STI treatment

0.46a

0.63a

Taking an HIV test

0.09

0.07a

Picking up the result of HIV test

0.02

0.22a


STEMI (n = 22)	NSTEMI (n = 11)	Total (n = 33)


Traitsa	SNPs	Chr.	Position (bp)	Allele	MAF	-Log10(P)	Allele's effect


 	Unadjusted odds ratio	p value	Adjusted odds ratio	p value

[95% confidence interval]	[95% confidence interval]

Adequate sleep	 	<.0001	 	.9812

 7 hours or more	Reference 	 	Reference

 Less than 7 hours 	1.34 [1.18, 1.52]	 	1.00 [0.83, 1.21]

Age group	 	 	 	<.0001

 30 to less than 45 years	 	 	Reference

 45 to less than 55 years	 	 	2.77 [2.04, 3.76]

 55 years and above	 	 	5.49 [3.77, 8.01]

Sex	 	 	 	<.0001

 Female	 	 	Reference

 Male	 	 	2.60 [2.17, 3.12]

Race/ethnicity

 Non-Hispanic white	 	 	Reference

 Non-Hispanic black	 	 	1.88 [1.20, 2.96]	.0060

 Hispanic	 	 	2.94 [2.18, 3.97]	<.0001

 Other	 	 	1.65 [1.13, 2.41]	.0092

Education	 	 	 	<.0001

 HS graduate/less	 	 	1.34 [1.09, 1.65]

 Some coll/tech/more	 	 	Reference

Smoking

 Current	 	 	2.74 [1.98, 3.80]	<.0001

 Former	 	 	1.43 [1.15, 1.79]	.0016

 Never	 	 	Reference

Number of missing teeth

 0–5	 	 	Reference

 6–9	 	 	1.44 [1.14, 1.82]	.0024

 10–20	 	 	2.64 [2.02, 3.44]	<.0001

 More than 20	 	 	2.18 [1.02, 4.65]	.0445

Federal Poverty Level Index

 0 to less than 1.25	 	 	1.82 [1.23, 2.71]	.0028

 1.25 to less than 2.00	 	 	1.62 [1.15, 2.26]	.0053

 2.00 to less than 4.00	 	 	1.60 [1.07, 2.39]	.0213

 4.00 and above	 	 	Reference

Insurance coverage	 	 	 	<.0001

 Yes	 	 	Reference

 No	 	 	1.73 [1.43, 2.10]

Diabetes	 	 	 	.1567

 Yes	 	 	1.41 [0.88, 2.26]

 No	 	 	reference

	Unadjusted odds ratio	p value

[95% confidence interval]

Adequate sleep		<.0001

7 hours or more	Reference

Less than 7 hours	1.34 [1.18, 1.52]

Age group

30 to less than 45 years

45 to less than 55 years

55 years and above

Sex

Female

Male

Race/ethnicity

Non-Hispanic white

Non-Hispanic black

Hispanic

Other

Education

HS graduate/less

Some coll/tech/more

Smoking

Current

Former

Never

Number of missing teeth

0–5

6–9

10–20

More than 20

Federal Poverty Level Index

0 to less than 1.25

1.25 to less than 2.00

2.00 to less than 4.00

4.00 and above

Insurance coverage

Yes

No

Diabetes

Yes

No


Primers	Sequence (5′–3′)

pmirGLO-HA-F	CTAGCTAGCAGCAAAAGCAGGGGAAAAC

pmirGLO-HA-R	CCGCTCGAGTAGTAGAAACAAGGGTGTTTTTTTC

pmirGLO-HA-mut-F	ATTAATGATATTCCGAAAGAAGTCC

pmirGLO-HA-mut-R	GGACTTCTTTCGGAATATCATTAAT

pmirGLO-NS-F	TACGAGCTCGCAAAAGCAGGGTGACAA

pmirGLO-NS-R	TGCTCTAGATAGTAGAAACAAGGGTGTTTTTTAT

pmirGLO-NS-mut-F	GATATCGAAACTCGGACTCTTGTTG

pmirGLO-NS-mut-R	CAACAAGAGTCCGAGTTTCGATATC

pmirGLO-PB1-F	TACGAGCTCAGCAAAAGCAGGCAAACC

pmirGLO-PB1-R	CCGCTCGAGTAGTAGAAACAAGGCATTTTTTCA

pmirGLO-PB2-F	CCGCTCGAGAGCAAAAGCAGGTCAAATATATT

pmirGLO-PB2-R	TGCTCTAGATAGTAGAAACAAGGTCGTTTTAAAC

pmirGLO-PA-F	TACGAGCTCAGCAAAAGCAGGTACTGATCC

pmirGLO-PA -R	CCGCTCGAGTAGTAGAAACAAGGTACTTTTTTGG

pmirGLO-NA-F	TACGAGCTCAGCAAAAGCAGGAGTTTAAAAT

pmirGLO-NA-R	CCGCTCGAGTAGTAGAAACAAGGAGTTTTTTGAAC

pmirGLO-NP-F	CCGCTCGAGAGCAAAAGCAGGGTAGATAATC

pmirGLO-NP-R	TGCTCTAGATAGTAGAAACAAGGGTATTTTTCCT

Primers	Sequence (5′–3′)

pmirGLO-PA -R	CCGCTCGAGTAGTAGAAACAAGGTACTTTTTTGG

pmirGLO-NA-F	TACGAGCTCAGCAAAAGCAGGAGTTTAAAAT

pmirGLO-NA-R	CCGCTCGAGTAGTAGAAACAAGGAGTTTTTTGAAC

pmirGLO-NP-F	CCGCTCGAGAGCAAAAGCAGGGTAGATAATC

pmirGLO-NP-R	TGCTCTAGATAGTAGAAACAAGGGTATTTTTCCT


Variables	No. of study (n = 28)	Coefficient (95% CI)	P value

Univariate meta-regression

Year of publication	28	0.03 (−0.03–0.08)	0.288

Male% in sample	28	0.001 (−0.01–0.02)	0.862

Sample size	28	0.00 (−0.00–0.00)	0.435

Study location

Inland	19	Reference

Coastal	9	−0.35 (−0.84–0.14)	0.153

Study region			0.054

South	5	Reference

Central	6	0.54 (−0.15–1.22)	0.119

North	17	0.71 (0.14–1.30)	0.017

Study period

2006–2012	18	Reference

1990–2005	10	−0.11 (−0.60–0.38)	0.656

Study setting			0.451

Rural and urban	4	Reference

Urban	21	0.39 (−0.29–1.06)	0.251

Rural	3	0.51 (−0.44–1.47)	0.278

Diagnostic criteria

15 μmol/L	25	Reference

Others	3	0.16 (−0.60–0.92)	0.671

Methods of Hcy measurement			0.798

FPIA	5	Reference

ECA	9	−0.10 (−0.81–0.62)	0.783

HPLC	8	0.07 (−0.66–0.80)	0.846

Others	6	0.22 (−0.55–1.00)	0.555

Multivariate meta-regression	0.0511

Year of publication	28	0.04 (−0.01–0.09)	0.242

Study location

Inland	19	Reference

Coastal	9	−0.16 (−0.70–0.38)	0.614

Study region			0.294

South	5	Reference

Central	6	0.48 (−0.25–1.21)	0.185

North	17	0.66 (−0.01–1.33)	0.052

Variables	No. of study (n = 28)	Coefficient (95% CI)

Univariate meta-regression

Year of publication	28	0.03 (−0.03–0.08)

Male% in sample	28	0.001 (−0.01–0.02)

Sample size	28	0.00 (−0.00–0.00)

Study location

Inland	19	Reference

Coastal	9	−0.35 (−0.84–0.14)

Study region

South	5	Reference

Central	6	0.54 (−0.15–1.22)

North	17	0.71 (0.14–1.30)

Study period

2006–2012	18	Reference

1990–2005	10	−0.11 (−0.60–0.38)

Study setting

Rural and urban	4	Reference

Urban	21	0.39 (−0.29–1.06)

Rural	3	0.51 (−0.44–1.47)

Diagnostic criteria

15 μmol/L	25	Reference

Others	3	0.16 (−0.60–0.92)

Methods of Hcy measurement

FPIA	5	Reference

ECA	9	−0.10 (−0.81–0.62)

HPLC	8	0.07 (−0.66–0.80)

Others	6	0.22 (−0.55–1.00)

Multivariate meta-regression

Year of publication	28	0.04 (−0.01–0.09)

Study location

Inland	19	Reference

Coastal	9	−0.16 (−0.70–0.38)

Study region

South	5	Reference

Central	6	0.48 (−0.25–1.21)

North	17	0.66 (−0.01–1.33)


	Al	Cd	Cu	Fe	Pb	Zn	Na	Ca	K	Mg	DOC	PH =	Temp.

P1	NS	*(0.89)	NS	NS	NS	NS	NS	NS	NS	NS	*(0.80)	*(0.85)	NS

P1.1	NS	*(0.82)	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS

P2	NS	*(0.82)	NS	NS	NS	NS	NS	NS	NS	NS	*(0.80)	*(0.86)	NS

P3	NS	NS	NS	NS	NS	NS	NS	*(0.90)	NS	NS	NS	NS	NS

P4	NS	NS	NS	NS	NS	NS	NS	*(0.90)	NS	NS	NS	NS	NS

P5	NS	NS	NS	NS	NS	NS	*(0.88)	NS	NS	NS	NS	NS	NS

P6	NS	NS	NS	NS	NS	NS	*(0.84)	NS	NS	NS	NS	NS	NS

G1	*(0.86)	NS	*(0.83)	‡(0.99)	‡(1.00)	*(0.80)	NS	NS	NS	NS	NS	NS	*(0.87)

G2	*(0.88)	NS	*(0.85)	‡(1.00)	‡ (1.00)	*(0.82)	NS	NS	NS	NS	NS	NS	*(0.89)

G3	NS	NS	NS	NS	NS	NS	*(0.91)	NS	NS	*(0.81)	NS	NS	NS

G4	NS	NS	NS	NS	NS	NS	†(0.94)	NS	NS	NS	NS	NS	NS

G5	NS	*(0.87)	NS	NS	NS	NS	NS	NS	NS	NS	NS	†(0.92)	NS

G6	NS	NS	NS	NS	NS	NS	†(0.94)	NS	NS	NS	NS	NS	NS

G7	NS	NS	NS	NS	NS	NS	NS	*(0.90)	NS	†(0.77)	NS	NS	NS

G8	NS	NS	NS	NS	NS	NS	†(0.94)	NS	NS	NS	NS	NS	NS

G9	NS	NS	NS	NS	NS	NS	NS	*(0.90)	NS	NS	NS	NS	NS

G10	NS	NS	NS	NS	NS	NS	†(0.93)	NS	NS	NS	NS	NS	NS

G11	*(0.85)	NS	*(0.82)	‡(0.98)	‡ (1.00)	†(0.79)	NS	NS	NS	NS	NS	NS	*(0.86)

G12	NS	NS	NS	NS	NS	NS	*(0.90)	NS	NS	NS	NS	NS	NS

G13	NS	NS	NS	NS	NS	NS	*(0.91)	NS	*(0.77)	NS	NS	NS	NS

G14	NS	NS	NS	NS	NS	NS	†(0.92)	NS	NS	NS	NS	NS	NS

G15	NS	*(0.89)	NS	NS	NS	NS	NS	NS	NS	NS	*(0.84)	†(0.93)	NS

G16	NS	NS	NS	NS	NS	NS	NS	*(0.90)	NS	*(0.78)	NS	NS	NS

G17	NS	NS	NS	NS	NS	NS	†(0.94)	NS	NS	NS	NS	NS	NS

G18	NS	NS	NS	NS	NS	NS	NS	*(0.87)	NS	NS	NS	NS	NS

G19	*(0.86)	NS	*(0.83)	‡(0.99)	‡(1.00)	*(0.80)	NS	NS	NS	NS	NS	NS	*(0.88)

G20	NS	NS	NS	NS	NS	NS	NS	†(0.93)	NS	*(0.82)	NS	NS	NS

G21	NS	NS	NS	NS	NS	NS	NS	*(0.91)	NS	*(0.78)	NS	NS	NS

G22	NS	NS	NS	NS	NS	NS	NS	*(0.85)	NS	NS	NS	NS	NS

G23	NS	NS	NS	NS	NS	NS	NS	*(0.90)	NS	NS	NS	NS	NS

G24	NS	NS	NS	NS	NS	NS	NS	*(0.90)	NS	*(0.77)	NS	NS	NS

G25	NS	*(0.86)	NS	NS	NS	NS	NS	NS	NS	NS	*(0.83)	†(0.93)	NS

	Al	Cd	Cu	Fe	Pb	Zn	Na	Ca

P1	NS	*(0.89)	NS	NS	NS	NS	NS	NS

P1.1	NS	*(0.82)	NS	NS	NS	NS	NS	NS

P2	NS	*(0.82)	NS	NS	NS	NS	NS	NS

P3	NS	NS	NS	NS	NS	NS	NS	*(0.90)

P4	NS	NS	NS	NS	NS	NS	NS	*(0.90)

P5	NS	NS	NS	NS	NS	NS	*(0.88)	NS

P6	NS	NS	NS	NS	NS	NS	*(0.84)	NS

G1	*(0.86)	NS	*(0.83)	‡(0.99)	‡(1.00)	*(0.80)	NS	NS

G2	*(0.88)	NS	*(0.85)	‡(1.00)	‡ (1.00)	*(0.82)	NS	NS

G3	NS	NS	NS	NS	NS	NS	*(0.91)	NS

G4	NS	NS	NS	NS	NS	NS	†(0.94)	NS

G5	NS	*(0.87)	NS	NS	NS	NS	NS	NS

G6	NS	NS	NS	NS	NS	NS	†(0.94)	NS

G7	NS	NS	NS	NS	NS	NS	NS	*(0.90)

G8	NS	NS	NS	NS	NS	NS	†(0.94)	NS

G9	NS	NS	NS	NS	NS	NS	NS	*(0.90)

G10	NS	NS	NS	NS	NS	NS	†(0.93)	NS

G11	*(0.85)	NS	*(0.82)	‡(0.98)	‡ (1.00)	†(0.79)	NS	NS

G12	NS	NS	NS	NS	NS	NS	*(0.90)	NS

G13	NS	NS	NS	NS	NS	NS	*(0.91)	NS

G14	NS	NS	NS	NS	NS	NS	†(0.92)	NS

G15	NS	*(0.89)	NS	NS	NS	NS	NS	NS

G16	NS	NS	NS	NS	NS	NS	NS	*(0.90)

G17	NS	NS	NS	NS	NS	NS	†(0.94)	NS

G18	NS	NS	NS	NS	NS	NS	NS	*(0.87)

G19	*(0.86)	NS	*(0.83)	‡(0.99)	‡(1.00)	*(0.80)	NS	NS

G20	NS	NS	NS	NS	NS	NS	NS	†(0.93)

G21	NS	NS	NS	NS	NS	NS	NS	*(0.91)

G22	NS	NS	NS	NS	NS	NS	NS	*(0.85)

G23	NS	NS	NS	NS	NS	NS	NS	*(0.90)

G24	NS	NS	NS	NS	NS	NS	NS	*(0.90)

G25	NS	*(0.86)	NS	NS	NS	NS	NS	NS

K	Mg	DOC	PH =	Temp.

NS	NS	*(0.80)	*(0.85)	NS

NS	NS	NS	NS	NS

NS	NS	*(0.80)	*(0.86)	NS

NS	NS	NS	NS	NS

NS	NS	NS	NS	NS

NS	NS	NS	NS	NS

NS	NS	NS	NS	NS

NS	NS	NS	NS	*(0.87)

NS	NS	NS	NS	*(0.89)

NS	*(0.81)	NS	NS	NS

NS	NS	NS	NS	NS

NS	NS	NS	†(0.92)	NS

NS	NS	NS	NS	NS

NS	†(0.77)	NS	NS	NS

NS	NS	NS	NS	NS

NS	NS	NS	NS	NS

NS	NS	NS	NS	NS

NS	NS	NS	NS	*(0.86)

NS	NS	NS	NS	NS

*(0.77)	NS	NS	NS	NS

NS	NS	NS	NS	NS

NS	NS	*(0.84)	†(0.93)	NS

NS	*(0.78)	NS	NS	NS

NS	NS	NS	NS	NS

NS	NS	NS	NS	NS

NS	NS	NS	NS	*(0.88)

NS	*(0.82)	NS	NS	NS

NS	*(0.78)	NS	NS	NS

NS	NS	NS	NS	NS

NS	NS	NS	NS	NS

NS	*(0.77)	NS	NS	NS

NS	NS	*(0.83)	†(0.93)	NS


Group	Material	Contrast	Region of main effect	Comparison with controls (increased/decreased, location)	Correlation with memory performance (location, correlating measure)

Controls	Words	Remembered > forgotten	Left HC

	Pictures		Bilateral PHG

	Faces		Right HC, A

	Words	Viewing > fixate	Left PHG

	Pictures		Left PHG

	Faces		Bilateral FG

Left TLE	Words	Remembered > forgotten	–	Increased, Right PHG	Right HC, 1/verbal recall

	Pictures		–	–	–

	Faces		Right HC, ERC	Increased, Right ERC	-

	Words	Viewing > fixate	Right PHG	Reduced, Left HC	Left HC, verbal recall

				Increased, Right PHG	Right HC, 1/verbal recall

	Pictures		Right PHG	Reduced, Left HC	Left HC, verbal learning

					Right HC, 1/verbal learning

	Faces		Right PHG, FG	Increased, Right FG	-

Right TLE	Words	Remembered > forgotten	Left HC	Increased, Left HC	-

	Pictures		Left PHG	-	Right HC, figure recall

	Faces		-	-	Left HC, 1/figure recall

					-

	Words	Viewing > fixate	-	Increased, Left HC	-

	Pictures		Left HC	Increased, Left HC	Right HC, figure recall

	Faces		Right HC	-	-

Group	Material	Contrast	Region of main effect	Comparison with controls (increased/decreased, location)	Correlation with memory performance (location, correlating measure)

	Pictures		Right PHG	Reduced, Left HC	Left HC, verbal learning

					Right HC, 1/verbal learning

	Faces		Right PHG, FG	Increased, Right FG	-

Right TLE	Words	Remembered > forgotten	Left HC	Increased, Left HC	-

	Pictures		Left PHG	-	Right HC, figure recall

	Faces		-	-	Left HC, 1/figure recall

					-

	Words	Viewing > fixate	-	Increased, Left HC	-

	Pictures		Left HC	Increased, Left HC	Right HC, figure recall

	Faces		Right HC	-	-


	Bivariate associations (n = 3438)	Adjusted odds ratios (n = 3293)

Increased = No	Increased = Yes	OR	95% CI1	AORa	95% CI1

n	(%)	n	(%)

Site Characteristics


Culture	MIC mode (μg/ml)a

Carb	Cpz	Gentb	Kanb	Levo	Nor	Rif	Tet	Vanc

M. smegmatis

pH 5.6		50		2.0		4.0	6.3

pH 6.6		50		2.0		2.0	25

pH 7.6		50		1.0		2.0	25


Solution Set	Health Status Level	Health Description	Maintenance Level

A1	Health (HS)	healthy condition	No maintenance

A2	Subhealth (SHS)	normal range	Preventive maintenance

A3	failure edge (FES)	fault edge	Corrective maintenance

A4	Failure (FS)	fault condition	Immediate maintenance


Reference	Study	# Cases	# Controls	Outcomes	Comment

[214]	Nurses' Health Study	3,483		↓folate intake + alcohol = ↑risk of breast cancer (OR = 0.55, P-trend = 0.001)	Folate intake not associated with overall risk of breast cancer

[215]	Canadian National Breast Screening Study	1,336	5,382	↓folate intake + alcohol = ↑risk of breast cancer (OR = 0.34, P-trend = 0.004)	Folate intake not associated with overall risk of breast cancer

[216]	Prospective study in USA with postmenopausal women	1,586		Among drinkers, ↓folate intake = ↑breast cancer risk (OR = 1.59)	No association in overall cohort

[125]	Shanghai Breast Cancer Study, China	1,321	1,382	↑folate intake = ↓ risk (OR = 0.71, P-trend = 0.05); ↑folate, ↑methionine, ↑B6, ↑B12 = ↓risk (OR = 0.47, P-trend = 0.01)	No alcohol, no supplements, unprocessed, unfortified foods

[217]	Nurses' Health Study II, study of premenopausal women	714		Vitamin A protective (OR = 0.28); Vitamins C, E, and folate not associated with risk.

[118]	Nurses' Health Study	712	712 matched	↑plasma folate = ↓risk (OR = 0.73, P-trend = 0.06). For women who drank alcohol, ↑plasma folate even more protective, OR = 0.11.	↑plasma B6 and plasma B12 were also protective

[218]	Prospective study in USA with postmenopausal women	1,823, 308 with family history (FH)		FH- +Alcohol = ↑risk (OR = 1.40) FH- + Alcohol + ↑folate = normal risk; FH+ ↓folate = ↑risk for drinkers (OR = 2.21) and non-drinkers (OR = 2.39); FH+ +Alcohol + ↑folate = ↑risk (OR = 1.67); FH+ + ↑folate = normal risk	Women with family history of breast cancer can reduce risk by increasing folate intake and not drinking.


	Formulations	Crystalline Phase (wt%)	Amorphous Phase (wt%)

	Pure Ca/Mg-rich glass	66	34

1	H62C + fillers	88	12

2	H62C + fillers + 10 wt% glass	98	2

3	MK + fillers	92	8

4	MK + fillers + 10 wt% glass	96	4


Number of HIV-negative people and people living in sub-national areas with incidence ≥3%	Number of HIV-negative people and people living in sub-national areas with incidence ≥1.5%

Characteristics	Estimates	Characteristics	Estimates

Women:• 15–19 years old• 20–24 years old	140,000770,000	Women: • 15–19 years old • 20–24 years old	2.2 million2.4 million

Men:• 15–19 years old• 20–24 years old	040,000	Men: • 15–19 years old • 20–24 years old	01.2 million

Countries: Kenya, Lesotho, Mozambique, South Africa, Swaziland.	Countries: Kenya, Lesotho, Mozambique, South Africa, Swaziland, Zimbabwe and Uganda.

Number of HIV-negative people and people living in sub-national areas with incidence ≥3%	Number of HIV-negative people and people living in sub-national areas with incidence ≥1.5%

Characteristics	Estimates	Characteristics	Estimates

Women:• 15–19 years old• 20–24 years old	140,000770,000	Women: • 15–19 years old • 20–24 years old	2.2 million2.4 million

Men:	040,	Men: • 15–19 years old • 20–24 yea	01.2 mill

• 15–19 years old• 20–24 years old	000	rs old	ion

Countries: Kenya, Lesotho, Mozambique, South Africa, Swaziland.	Countries: Kenya, Lesotho, Mozambique, South Africa, Swaziland, Zimbabwe and Uganda.


Groups	Specific Diseases (ICD-10 Coding) [Number of GPs Mentioning It]

ICD-10 E86 Volume depletion/ E87 Other disorders of fluid, electrolyte and acid-base balance [22/24]	E86 Volume depletion OR T67.3 Heat exhaustion due to water depletion [18]

E87 Other disorders of fluid, electrolyte and acid-base balance OR T67.4 Heat exhaustion due to salt depletion [4]

Circulatory diseases, ICD10-I00-I99 [15/24]	I99 Other and unspecified disorders of circulatory system [9]: usually naming circulatory collapse and circulatory dysregulation

I95 Hypotension [4]

Other [3]: I74 Arterial embolism and thrombosis [1], I64 Stroke, not specified as hemorrhage or infarction [1], I49.9 Cardiac arrhythmia, unspecified [1]

T67 Effects of heat and light [8/24]	T67.6 Heat fatigue, transient [5]; T67.0 Heatstroke and sunstroke [3]; T67.5 Heat exhaustion, unspecified [2], T67.1 Heat syncope [2]; T76.7 Heat edema [1]

Infectious diseases, ICD10-A00-B99 [7/24]	A00–A09 Intestinal infectious diseases [6]

Other [3]: B37.2 Candidiasis of skin and nail [1], L00–L08 Infections of the skin and subcutaneous tissue [2], N39.0 Urinary tract infection, site not specified [1]

Organic mental disorders, ICD-F00-F09 [5/24]	Disorientation, cognitive or emotional impairment [4] (in line with F05–F07 *)

Aggravation of dementia [2] (F00–F003)

Others [5/24]	N17 Acute renal failure [2]; J98.9 Respiratory disorder, unspecified [1]; L55 Sunburn [1]; Injuries from fall [3]

Groups	Specific Diseases (ICD-10 Coding) [Number of GPs Mentioning It]

ICD-10 E86 Volume depletion/ E87 Other disorders of fluid, electrolyte and acid-base balance [22/24]	E86 Volume depletion OR T67.3 Heat exhaustion due to water depletion [18]

E87 Other disorders of fluid, electrolyte and acid-base balance OR T67.4 Heat exhaustion due to salt depletion [4]

Circulat	I99 Other and unspecified disorders of circulatory system [9]: usually naming circulatory collapse and circulatory dysregulatio

Groups	Specific Diseases (ICD-10 Coding) [Number of GPs Mentioning It]

ory diseases, ICD10-I00-I99 [15/24]	n

I95 Hypotension [4]

Other [3]: I74 Arterial embolism and thrombosis [1], I64 Stroke, not specified as hemorrhage or infarction [1], I49.9 Cardiac arrhythmia, unspecified [1]

T67 Effects of heat and light [8/24]	T67.6 Heat fatigue, transient [5]; T67.0 Heatstroke and sunstroke [3]; T67.5 Heat exhaustion, unspecified [2], T67.1 Heat syncope [2]; T76.7 Heat edema [1]

Infectious diseases, ICD10-A00-B99 [7/24]	A00–A09 Intestinal infectious diseases [6]

Other [3]: B37.2 Candidiasis of skin and nail [1], L00–L08 Infections of the skin and subcutaneous tissue [2], N39.0 Urinary tract infection, site not specified [1]

Organic mental disorders, ICD-F00-F09 [5/24]	Disorientation, cognitive or emotional impairment [4] (in line with F05–F07 *)

Aggravation of dementia [2] (F00–F003)

Others [5/24]	N17 Acute renal failure [2]; J98.9 Respiratory disorder, unspecified [1]; L55 Sunburn [1]; Injuries from fall [3]


Question	n (%)

Do customers talk about experiences of trying to quit smoking?

 Yes many do	30 (73)

 Yes some do	9 (22)

 No	1 (2)

 No response	1 (2)

Do customers ask for advice about quitting?

 Yes	37 (90)

 No	3 (7)

 No response	1 (2)

What kind of information do you give to customers? (multiple responses permitted)

 Product information	38 (93)

 Smoking cessation advice	17 (41)

 Information how to cut down regular cigarettes	36 (88)

 Other	9 (22)

Where do you access this information? (Open question)

 Online	22 (54)

 In-house training	6 (15)

 Personal experience	10 (24)

 Manufacturers' guidelines	3 (7)

How confident are you about offering smoking cessation advice to customers that ask for it?

 Not at all	0 (0)

 Not too confident	2 (5)

 Quite confident	15 (37)

 Very confident	16 (39)

 No response	8 (20)

Do you think it would be a good idea to deliver smoking cessation advice with training in your shop?

 Yes	19 (46)

 No	4 (10)

 Not sure	17 (41)

 No response	1 (2)

Do you think customers would be interested in accessing this in-store smoking cessation service?

 Yes	17 (41)

 No	9 (22)

 Not sure	15 (37)

Which type of in-store cessation service do you think might work best? (n = 19 - staff who think service is a good idea)

 Support from a training member of staff	14 (74)

 Face-to-face support from an external advisor	1 (5)

 A text or email-based support service	0 (0)

 No response	4 (21)

Question	n (%)

What kind of information do you give to customers? (multiple responses permitted)

Product information	38 (93)

Smoking cessation advice	17 (41)

Information how to cut down regular cigarettes	36 (88)

Other	9 (22)

Where do you access this information? (Open question)

Online	22 (54)

In-house training	6 (15)

Personal experience	10 (24)

Manufacturers' guidelines	3 (7)

How confident are you about offering smoking cessation advice to customers that ask for it?

Not at all	0 (0)

Not too confident	2 (5)

Quite confident	15 (37)

Very confident	16 (39)

No response	8 (20)

Do you think it would be a good idea to deliver smoking cessation advice with training in your shop?

Yes	19 (46)

No	4 (10)

Not sure	17 (41)

No response	1 (2)

Do you think customers would be interested in accessing this in-store smoking cessation service?

Yes	17 (41)

No	9 (22)

Not sure	15 (37)

Which type of in-store cessation service do you think might work best? (n = 19 - staff who think service is a good idea)

Support from a training member of staff	14 (74)

Face-to-face support from an external advisor	1 (5)

A text or email-based support service	0 (0)

No response	4 (21)


Characteristics of patients	100

Phototype

I	0 (0%)

II	72 (72%)

III	28 (28%)

IV	0 (0%)

V	0 (0%)

Skin hydration

dry skin	56 (56%)

normal skin	10 (10%)

sensible skin	34 (34%)

Characteristics of patients	100

Phototype

I	0 (0%)

I	72

Characteristics of patients	100

I	(72%)

III	28 (28%)

IV	0 (0%)

V	0 (0%)

Skin hydration

dry skin	56 (56%)

normal skin	10 (10%)

sensible skin	34 (34%)


	Rate ratio (95% CIa)	Intervention effect ratiob

	(intervention period relative to baseline)	(95% CIa)

Outcome variable	Intervention	Control

ISH presentations and self-inflicted death events	0.91 (0.81–1.02)	0.85 (0.76–0.95)	1.07 (0.82–1.40)

ISH presentations only	0.91 (0.80–1.02)	0.85 (0.75–0.95)	1.07 (0.82–1.40)

Self-inflicted death events only	1.17 (0.84–1.65)	1.01 (0.77–1.31)	1.18 (0.51–2.70)

	Rate ratio (95% CIa)	Intervention effect ratiob

	(intervention period relative to baseline)	(95% CIa)

Outcome variable	Intervention	Control

ISH presentations only	0.91 (0.80–1.02)	0.85 (0.75–0.95)	1.07 (0.82–1.40)

Self-inflicted death events only	1.17 (0.84–1.65)	1.01 (0.77–1.31)	1.18 (0.51–2.70)


Responses (verbatim)	Number of health workers (n=10)	Percentage (%)

We usually ask if they had finished the treatment	1	10

When they come we check the container, most have finishedbut others did not finish due to nausea and vomiting. Thosewho did not finish we educate them	1	10

We repeat Hb test	1	10

Through statistics records	1	10

We interview, the questions are like how is the progress, ifthey are complying; and if they have problems they usuallytell us	1	10

We ask mothers to accompany teenagers and ask the motherabout compliance	1	10

We give them 28 day supply, if after 4 weeks they still havesupplements we know they are not complying	1	10

You give them health education, if they understand you aresure they are going to comply	1	10

We only hear from them if they complain with side effects, ifno complain they are complying	1	10

Usually ask questions and check Hb levels	1	10

Responses (verbatim)	Number of health workers (n=10)

We usually ask if they had finished the treatment	1

When they come we check the container, most have finishedbut others did not finish due to nausea and vomiting. Thosewho did not finish we educate them	1

We repeat Hb test	1

Through statistics records	1

We interview, the questions are like how is the progress, ifthey are complying; and if they have problems they usuallytell us	1

We ask mothers to accompany teenagers and ask the motherabout compliance	1

We give them 28 day supply, if after 4 weeks they still havesupplements we know they are not complying	1

You give them health education, if they understand you aresure they are going to comply	1

We only hear from them if they complain with side effects, ifno complain they are complying	1

Usually ask questions and check Hb levels	1


Phantom configuration	True sphere/background ratio	SPECT alone	SPECT-CT

		Isocontour (%)	Measured volume (cm3)	Error (%)	Isocontour (%)	Measured volume (cm3)	Error (%)


Instruments	Categories	Variables

Baseline questionnaire	Demographic characteristics	Age; Sex; Nationality; Education; Occupation; Marriage; Family income of last year; Health insurance, etc.

	Family history	Liver, renal and other disease history of family members.

	Medical history and concurrent disease	Previous hepatitis history; Previous hepatitis virus tests results. Diagnosis and duration of past renal, visional, auditive and other chronic disease history; Allergic history; Concurrent chronic diseases.

	TB diagnosis and previous treatment	Definitive diagnosis of TB; Diagnosis time; Diagnosis agency; Anti-TB treatment history; Anti-tuberculosis induced ADEs occurrence history.

	Current drug usage information	Product name; Production NO; Dose; Method and cost of anti-tuberculosis drugs and other concurrent using drugs.

Physical, laboratory examination	Physical examinations	Height; Weight.

	Blood routine test	Erythrocyte count (1012/L); Leukocyte count (109/L); Hemoglobin concentration (g/L); Platelet count (109/L).

	Urine routine test	PH value; Urine protein; Erythrocyte count; Leukocyte count; Urinary cylinder count.

	Liver and renal function test	Alanine aminotransferase (ALT, U/L); Aspartate aminotransferase (AST, U/L); Total bilirubin (TBIL, μmol/L); Blood urea nitrogen (BUN, mmol/L).

	Hepatitis B virus marker	HBsAg test.

Medication record	Anti-TB drugs	Name, commercial name, manufacturer, production number, usage, dosage, starting and ending time of anti-TB drugs, including RHZES and other supplementary anti-TB drugs.

	Liver protective drugs	Name, commercial name, manufacturer, production number, usage, dosage, starting and ending time of drugs used for preventing ATLI.

	Other drugs	Name, commercial name, manufacturer, production number, usage, dosage, starting and ending time of other drugs used during the anti-TB therapy, for example, antihypertensive drugs, hypoglycaemic drugs, etc.

Categories	Variables

Other drugs	Name, commercial name, manufacturer, production number, usage, dosage, starting and ending time of other drugs used during the anti-TB therapy, for example, antihypertensive drugs, hypoglycaemic drugs, etc.


model	traditional method

	Sensitivity (%)	Specificity (%)	Sensitivity (%)	Specificity (%)

≤ T2	84.1	96.1	41.3	96.3

T3	81.8	89.7	27.3	69

T4	95.2	94.6	85.7	61.2

model

	Sensitivity (%)

≤ T2	84.1

T3	81.8

T4	95.2

model	traditional method

Specificity (%)	Sensitivity (%)	Specificity (%)

96.1	41.3	96.3

89.7	27.3	69

94.6	85.7	61.2


		Within population a	Between populations b

Chr	Site	Pop. c	π	Tajima’s D	MAF	FU	FW

A	0-fold	RG	0.0012	−0.8397	0.1222	0.1516	0.1709

		FR	0.0010	−0.2586

	4-fold	RG	0.0154	−0.1069	0.1653	0.1684	0.1743


Age	Sex	Start [g]	Final eu [g]	Final hyper [g]	Final hypo [g]

Adult	Males	40.2 ± 5.0	45.8 ± 3.7 **	40.1 ± 4.1	35.6 ± 2.0 *

Age	Sex	Start [g]	Final eu [g]	Final hyper [g]	Final hypo [g]

Adult	Females	28.0 ± 1.4††††	30.5 ± 3.1††	34.3 ± 2.2 ***	27.0 ± 1.6

Old	Males	39.0 ± 5.2	41.3 ± 3.7	36.9 ± 5.3	34.0 ± 3.1 *

Females	30.3 ± 3.5††††	32.8 ± 3.2††††	33.7 ± 4.4†	28.7 ± 1.7††††


Variables	Frequency (%)

Sex

 Male	363 (58.8)

 Female	254 (41.2)

Age (years, n = 569)

 15–19	75 (13.2)

 20–24	451 (79.3)

≥ 25	43 (7.3)

Religion

 Orthodox	540 (87.5)

 Muslim	29 (4.7)

 Protestant	44 (7.1)

 Other	4 (0.7)

Region

 Tigray	37 (6.0)

 Amhara	274 (44.4)

 Oromia	59 (9.6)

 SNNP	31 (5.0)

 Addis Ababa	136 (22.0)

 Othera	8 (1.34)

Income Category (in birr)

 ≤ 500	306 (68.8)

 501–1000	92 (20.7)

 ≥ 1001	47 (10.6)

Mother’s Educational Status

 Not Educated	277 (44.9)

 Primary school	134 (21.7)

 Diploma	55 (8.9)

 Degree and above	67 (10.9)

Father’s Educational Status

 Not Educated	213 (34.5)

 Secondary school	71 (11.5)

 Diploma	56 (9.1)

 Degree and above	126 (20.4)

Preparatory School

 Public	547(88.7)

 Private	63 (10.2)

 NGO	7 (1.1)


Group	N	Pain intensity

		D1

Group I	50	0.62 ± 0.6*

Group II	50	1.64 ± 0.9*


Popul	Vaccinees(CT n = 24	Non vaccine	p-valu


SIMD quintile & domain	Mean score out of 10 & (SD)	Developmentally vulnerable	Developmentally at risk	On track

		In the lowest 10%	Between the 10th and the 25th percentile	Between the 25th and 50th percentile	Above the 50% percentile

		%	%	%	%

C&GK	8.78 (1.93)	5.6	15.0	79.4	0


Fixed effects	Coefficient value	Standard error	Degrees of freedom	P-valuea

Intercept	44.917	0.776	57	<.0001

D530c vs. D-SPECT	−26.300	1.049	12	<.0001

A-SPECT vs. D-SPECT	−37.779	1.021	12	<.0001

Slope for the D-SPECT	−1.747	0.072	57	<.0001

Slope for the D530c	0.277	0.043	57	<.0001

Slope for the A-SPECT	−0.022	0.007	57	0.0016

Random effects	Standard deviation	Standard deviation adjustment per camera

Intercept	1.42	D-SPECT	D530c	A-SPECT

Residual	0.497	1	0.706	0.108

Fixed effects	Coefficient value	Standard error	Degrees of freedom	P-valuea

Intercept	44.917	0.776	57	<.0001

D530c vs. D-SPECT	−26.300	1.049	12	<.0001

A-SPECT vs. D-SPECT	−37.779	1.021	12	<.0001

Slope for t	−1.747	0	5	<.0

Fixed effects	Coefficient value	Standard error	Degrees of freedom	P-valuea

he D-SPECT		.072	7	001

Slope for the D530c	0.277	0.043	57	<.0001

Slope for the A-SPECT	−0.022	0.007	57	0.0016

Random effects	Standard deviation	Standard deviation adjustment per camera

Intercept	1.42	D-SPECT	D530c	A-SPECT

Residual	0.497	1	0.706	0.108


	Continuous level (1/day)	p-value	Level of soy consumptionb

			Quartile 1	Quartile 2	Quartile 3	Quartile 4

Total soy

Median intake, svg/wk			0.0	4.5	13.5	24.2

Median AOM, yrc			12.6	12.4	12.5	12.6


	Workpiece	Upper Punch	Die	Lower Punch

Properties	Elastic-plastic	Rigid

Material	C1010	SKH55	WC	SKH9

Mesh number	35,000	30,000

Hardness	HRC38	HRC66	HRC77	HRC61

	Workpiece

Properties	Elastic-plastic

Material	C1010

Mesh number	35,000

Hardness	HRC38

Upper Punch	Die	Lower Punch

Rigid

SKH55	WC	SKH9

30,000

HRC66	HRC77	HRC61


ID	No-Attr BE	Sex BE	Age BE	Ped BE	All-Attr BE	All-Attr BE+CE	SSABE	SSABEG


LogMAR BCVA	Phacotrab group	Phaco group	P Value

Mean preoperative ± SD	1.21 ± 0.49	1.23 ± 0.43	0.93*

Mean postoperative ± SD (6 mos)	0.82 ± 0.44	0.80 ± 0.38	0.91*

Mean postoperative ± SD (12 mos)	0.82 ± 0.41	0.80 ± 0.39	0.85*

P Value	0.003*	<0.001*

LogMAR BCVA	Phacotrab group	Phaco group	P Value

Mean preoperative ± SD	1.21 ± 0.49	1.23 ± 0.43	0.93*

Mean postoperative ± SD (6 mos)	0.82 ± 0.44	0.80 ± 0.38	0.91*

Mean postoperative 	0.82 ± 0.41	0	0.85


P of chi-square	I2	Selected model	P for overall effect

0	92 %	Random-effect model	0.003

0.564	0 %	Fixed-effect model	<0.001

0.673	0 %	Fixed-effect model	<0.001

0.003	78 %	Random-effect model	0.013

0.138	46 %	Fixed-effect model	0.015

0.552	0 %	Fixed-effect model	<0.001

0.001	95 %	Random-effect model	0.030


	Normal	1	2	3	4	5	6

Motor

 Median nerve

DML (ms)	≤ 3,9	2,8	3		3,8	5

NCV (m/s)	≥ 50	53	50	n.d.	46,2	56	n.d.

Amplitude (mV)	≥ 6	11,4	14,2		n.d.	11

 Peroneal nerve

DML (ms)	≤ 4,8	7,6	4		5,3

NCV (m/s)	≥ 42	37	45	not recordable	47,8	not recordable	not recordable

Amplitude (mV)	≥ 4	0,8	8,4		2

 Tibial nerve

DML (ms)	≤ 5,1	6,2	4,2	7,1

NCV (m/s)	≥ 41	31	36	38	n.d.	not recordable	not recordable

Amplitude (mV)	≥ 5	0,6	0,4	0,4

Sensory

 Median nerve

NCV (m/s)	≥ 47	60	54	n.d.	57,7	45	n.d.

Amplitude (mV)	≥ 7	13,4	11		n.d.	20

 Sural nerve

NCV (m/s)	≥ 41	34	not recordable	30	56,5	32	not recordable

Amplitude (mV)	≥ 10	7,2		1	n.d.	6


	Males	P	Females	P

	(n = 24)		(n = 20)

Model R	0.28	0.80	0.79	0.004

Standardised coefficients (Beta)

BMI	−0.06	0.88	1.06	0.008


All others			1

Income (n° of minimal wages)	0.054	0.026	1.056	1.007 – 1.107


Expression	Gene	Meningioma (%)	Schwannoma (%)

Downregulation	FOS	90	65

ICAM1	71	61

FLY1	78	48

Upregulation	ITCAV	66	61

Downregulation	FLY1	78	48

Upregulation	ITCAV	66	61


Cluster number	x, y, za	Peak intensity	Cluster sizeb	Regionc	Brodmann's area

Taking the Declive as ROI

1	−30, 3, −18	3.649	142	L Superior Temporal Gyrus/Inferior Parietal Lobe	41, 42, 44, 45

2	12, −72, 27	−3.462	125	R Medial Frontal Gyrus	7

3	−21, −27, 60	3.764	189	L Precentral Gyrus	4, 6

Taking the Precentral Gyrus as ROI

1	0, 27, −21	−5.278	136	Orbital Frontal Gyrus	8, 9

2	3, 27, 39	4.077	497	Superior Frontal Gyrus/Medial Frontal Gyrus	4, 6, 8, 9

Taking the Striatum as ROI

1	9, 0, 54	3.632	151	R Anterior Cingulate Cortex	6, 23, 24

2	39, −24, 48	3.884	185	R Middle Frontal Gyrus	4

R Inferior Frontal Gyrus

3	−24, 6, 51	3.749	197	L Postcentral Gyrus	1, 2, 3


Time of assessment	n	Mean	Median	Minimum	Maximum	SD	P-value*

Preoperative	30	4.1	4.0	2.0	8.3	1.4

3-5 days	30	3.3	3.1	1.8	4.9	0.8


Typer	Overall	HLA-A	HLA-B	HLA-C

Optitype (4-digit)	0.09	0.08	0.08	0.11

Polysolver (8-digit)	0.08	0.08	0.02	0.14

Polysolver (4-digit)	0.12	0.12	0.09	0.15


Characteristics	New-onset CAE (n = 35)	Control (n = 33)	P value

Age (years), mean ± SD (range)	7.3 ± 1.3 (5–10)	6.8 ± 1.1 (5–9)	0.14

Gender (boys/girls)	14/21	18/15	0.23

Age at onset, years (SD)	6.7 (1.3)	N/A	N/A

Duration of epilepsy (time to diagnosis), months (SD)	7 (7)	N/A	N/A


BehaviouralCorrelate	Brain region	Cerebral hemisphere	Cluster size (voxels)	p value

Combined groups	Anterior TL, OFC	R	107,453	0.02

bvFTD only	Anterior TL, OFC	Bilateral	318,805	0.01

bvFTD > svPPA	Parahippocampal, fusiform gyri	L	61,222	0.03

BehaviouralCorrelate	Brain region	Cerebral hemisphere	Cluster size (voxels)	p value

Combined groups	Anterior TL, OFC	R	107,453	0.02

bvFTD only	Anterior TL, OFC	Bilateral	318,805	0.01

bvFTD > 		L	61,22	0.03


Variable	C	F

Glucose (mg/dl)	83.6 ± 4.5	98.5 ± 10.5*

Triglycerides (mg/dl)	123.4 ± 49.0	268.3 ± 35.1*

Total cholesterol (mg/dl)	91.7 ± 9.6	96.3 ± 15.5

HDL cholesterol (mg/dl)	42.7 ± 5.3	43.5 ± 6.9

LDL cholesterol (mg/dl)	62.8 ± 3.9	65.4 ± 1.3

AST/ALT ratio	1.08 ± 0.4	2.8 ± 0.8*

SOD (U/ml)	1.7 ± 0.4	1.5 ± 0.6


	Normal versus normal-tension glaucoma

AUROC (SE)

OCT-A whole image vessel density	0.950 (0.027)

OCT-A inside disc vessel density	0.931 (0.034)

OCT-A peripapillary vessel density	0.830 (0.056)∗

LSFG MBRA	0.793 (0.065)∗†

LSFG MBRV	0.601 (0.079)∗†‡

LSFG MBRT	0.601 (0.079)∗†‡

GCC thickness	0.970 (0.021)‡

RNFL thickness	0.906 (0.039)


Private Hospital	National Data

YEAR	No. of Malaria cases	Plasmodium falciparum	YEAR	No. of Malaria Cases	Plasmodium falciparum

2006July -December	60	31	2006	928	36

2007	35	15	2007	182	2

2008Jan - July	18	10	2008	248	0

Private Hospital	National Data

YEAR	No. of Malaria cases	Plasmodium falciparum	YEAR	No. of Malaria Cases	Plasmodium falciparum

2008Jan - July	18	10	2008	248	0


	Group I (Harvesting)	Group II (Preserving)	p value*

Patients	61 (10 M & 51 F)	43 (1 M & 42 F)

Age (years)	14.0 (11 ~ 19)	13.8 (10 ~ 18)	0.71

Median f/u length (months)	60 (24 ~ 128)	73 (24 ~ 107)

Level fused	10.6 ± 1.7	10.0 ± 1.9	0.06

Duration of surgery (minutes)	216 ± 47	224 ± 50	0.40

Implants inserted (numbers)	13.3 ± 2.2	13.3 ± 2.0	0.97

Blood loss (ml)	983 ± 446	824 ± 361	0.048

Peri-OP blood transfusion (units)	6.0 ± 3.3	5.1 ± 3.0	0.13

Hospitalization length (days)	7.4 ± 1.0	6.8 ± 0.8	0.003

	Group I (Harvesting)	Group II (Preserving)	p value*

Patients	61 (10 M & 51 F)	43 (1 M & 42 F)

Age (ye		13.8 (10 ~	0

ars)	14.0 (11 ~ 19)	 18)	.71

Median f/u length (months)	60 (24 ~ 128)	73 (24 ~ 107)

Level fused	10.6 ± 1.7	10.0 ± 1.9	0.06

Duration of surgery (minutes)	216 ± 47	224 ± 50	0.40

Implants inserted (numbers)	13.3 ± 2.2	13.3 ± 2.0	0.97

Blood loss (ml)	983 ± 446	824 ± 361	0.048

Peri-OP blood transfusion (units)	6.0 ± 3.3	5.1 ± 3.0	0.13

Hospitalization length (days)	7.4 ± 1.0	6.8 ± 0.8	0.003


Station	Sampling date	Water depth (m)	Water temperature (°C)	Salinity (psu)	Flow velocity (mm s-1)

H1	Oct 25, 2012	3.8	16.0	25.0	129 ± 70

A3	Apr 3, 2013	3.4	19.1	19.4	818 ± 172

A5	Apr 4, 2013	7.3	19.2	30.1	713 ± 498

Station	Sampling date	Water depth (m)	Water temperature (°C)	Salinity (psu)	Flow velocity (mm s-1)

A5	Apr 4, 2013	7.3	19.2	30.1	713 ± 498


Health education mode	Medical and health information from friends’ moments, group chats, public account sharing (open to all)	Normal health education information from the doctor in charge of you	Personalized health education information from the doctor in charge of you	Personalized health education information from the doctor in charge of you, and reminders for you (for example, referred to you, @ you, private letter to you)

Score	61.40	70.15	74.15	76.42


CMs modalities	Level of need

No %	Low %	Moderate %	High %	Some %

Herbal medicines	10	31	47	13	90

Vitamins, minerals, trace elements	7	35	46	13	93

Nutritional supplements	10	34	46	11	90

Homeopathic preparations	45	36	15	4	55

Aromatherapy products	50	37	10	4	50

Dietary interventions	12	27	43	18	88


Factor	mean± SD	Min	Max

ECD (superior)	2748.9±206.9	2245	3254

ECD (superotemporal)	2751.3±231.01	2321	3345


 	Group 1	Group 2	Group 3	P*

Healthy children	Ambulant sick children	Non ambulant sick children

 	n = 126	n = 99	n = 36

 	(%1)	(%1)	(%1)

Direct benefits to the parent’s own child of participating in the study	85.7	100.0	100.0	0.88

Benefits to the general population	93.6	87.2	27.6	0.001

Low risk to the child of participating in the study	100.0	60.8	70.2	0.04

Understanding the study and its regulation	66.7	57.4	13.8	0.001